Clinical Insights: April 3, 2024
Welcome to Pillr Health’s Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace.
New Drug/Vaccine Approval
Voydeya™ (danicopan) Tablets – New Drug Approval – March 29, 2024 – Voydeya™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH). Voydeya™ is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris® (ravulizumab) or Soliris® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor. <Read More> Vafseo® (vadadustat) Tablets – New Drug Approval – March 27, 2024 – Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo® is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo® is now approved in 37 countries. <Read More> Winrevair™ (sotatercept) for Injection – New Orphan Drug Approval – March 26, 2024 – Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has approved sotatercept-csrk (U.S. Brand Name: Winrevair™, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. Winrevair™ was previously granted Breakthrough Therapy Designation by the FDA. Winrevair™ is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH. <Read More> Opsynvi® (macitentan and tadalafil) Tablets – New Orphan Drug Approval – March 22, 2024 – Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Opsynvi® – a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor – for the chronic treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group I) and WHO functional class (FC) II-III. Opsynvi® may be used in patients with PAH who are treatment-naïve or who are already on an ERA, PDE5 inhibitor or both. Opsynvi® may be used in patients who are currently treated concomitantly with stable doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets. <Read More> Duvyzat™ (givinostat) Oral Suspension – New Orphan Drug Approval – March 21, 2024 – The U.S. Food and Drug Administration approved Duvyzat™ (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat™ is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle. <Read More> Tryvio™ (aprocitentan) Tablets – New Drug Approval – March 20, 2024 – Idorsia Ltd (SIX: IDIA) announced that the US Food and Drug Administration (FDA) has approved Tryvio™ (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. The recommended dosage of Tryvio™ is 12.5 mg orally once daily, with or without food. <Read More>
New Indication/Dosage/Formulation Approval
Vemlidy® (tenofovir alafenamide) Tablets – New Label Expansion – March 27, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease. <Read More> Elahere® (mirvetuximab soravtansine-gynx) Injection – New Label Expansion – March 22, 2024 – AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Elahere® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies. Patients with these cancers often present with late-stage disease, undergo surgery and are then treated with platinum-based chemotherapy. They may become resistant to this treatment and require another therapy, such as Elahere®. <Read More> Nexletol® (bempedoic acid) and Nexlizet® (bempedoic acid and ezetimibe) Tablets – New Label Expansion – March 22, 2024 – Esperion (NASDAQ: ESPR) announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for Nexletol® (bempedoic acid) Tablets and Nexlizet® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients. In addition, the enhanced labels support the use of Nexletol® and Nexlizet® either alone or in combination with statins. They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients. <Read More> Ultomiris® (ravulizumab-cwvz) Injection – New Label Expansion – March 22, 2024 – Ultomiris® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology. In the trial, Ultomiris® was compared to an external placebo arm from the pivotal Soliris PREVENT clinical trial. <Read More> Ixinity® (coagulation factor IX (recombinant)) for Injection – New label Expansion – March 22, 2024 – Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) announced that the US Food and Drug Administration (FDA) recently approved Medexus's supplemental Biologics License Application (sBLA) for Ixinity® [coagulation factor IX (recombinant)] for the on-demand, prophylactic, and perioperative treatment of pediatric patients under 12 years of age with hemophilia B. Ixinity®, an intravenous recombinant factor IX therapeutic, is now approved for use in all patients with hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood. <Read More> Iclusig® (ponatinib) Tablets – New Label Expansion – March 19, 2024 – Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Iclusig® (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This accelerated approval application was granted Priority Review and evaluated under the Real-Time Oncology Review (RTOR) program, an FDA initiative designed to expedite the delivery of cancer medicines by allowing components of an application to be reviewed before submission of the complete application. <Read More> Spevigo® (spesolimab-sbzo) Injection – New Label Expansion – March 18, 2024 – Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has approved Spevigo® (spesolimab-sbzo) injection for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 and above weighing ≥40 kg. This approval follows the Chinese National Medical Products Administration’s (NMPA) recent approval of Spevigo® for the reduction of occurrence of generalized pustular psoriasis (GPP) in adolescents from 12 years of age with a body weight ≥40 kg and adults. Spevigo® is a novel, humanized selective IgG1 antibody that binds to interleukin-36 receptor (IL-36R), a key part of a signaling pathway within the immune system shown to be involved in the cause of GPP. <Read More>
New Drug Shortage
March 28, 2024
Fluconazole Tablet (Discontinuation)
Linezolid Tablet (Discontinuation)
March 27, 2024
Insulin Lispro Injection (Discontinuation)
March 26, 2024
Azithromycin for Suspension (Discontinuation)
Barium Sulfate Cream (Discontinuation)
Carbidopa and Levodopa Tablet (Discontinuation)
March 25, 2024
Oxaliplatin Injection (Discontinuation)
March 22, 2024
Somatropin Injection (Discontinuation)
Updated Drug Shortage
April 02, 2024
Epinephrine Injection, Syringes (Currently in Shortage)
April 01, 2024
Azacitidine Injection (Currently in Shortage)
Dexamethasone Sodium Phosphate Injection (Currently in Shortage)
Erythromycin Ointment (Currently in Shortage)
Flurazepam Hydrochloride Capsule (Currently in Shortage)
Ropivacaine Hydrochloride Injection (Currently in Shortage)
Sodium Chloride 0.9% Irrigation (Currently in Shortage)
Sterile Water Irrigant (Currently in Shortage)
Tirzepatide Injection (Currently in Shortage)
March 29, 2024
Cromolyn Sodium Concentrate (Currently in Shortage)
Gentamicin Sulfate Injection (Discontinuation)
March 28, 2024
Atropine Sulfate Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Cytarabine Injection (Currently in Shortage)
Dexmedetomidine Hydrochloride Injection (Currently in Shortage)
Dextrose Monohydrate Injection (Currently in Shortage)
Disopyramide Phosphate Capsule (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Etomidate Injection (Currently in Shortage)
Gentamicin Sulfate Injection (Currently in Shortage)
Hydrocortisone Sodium Succinate Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Methotrexate Sodium Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Potassium Acetate Injection (Currently in Shortage)
Rocuronium Bromide Injection (Currently in Shortage)
Sodium Acetate Injection (Currently in Shortage)
Sodium Chloride 14.6% Injection (Currently in Shortage)
Sodium Chloride 23.4% Injection (Currently in Shortage)
Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate Injection (Currently in Shortage)
Sulfasalazine Tablet (Currently in Shortage)
March 25, 2024
Vecuronium Bromide Injection (Currently in Shortage)
New Drug Recall and Safety Alerts
Atovaquone Oral Suspension, USP 750 mg/5 mL by AvKARE, LLC. – New Voluntary Recall – April 1, 2024 - AvKARE, LLC. is voluntarily recalling lot # AW0221A of Atovaquone Oral Suspension, USP 750mg/5mL to the Consumer/User level, due to the potential Bacillus cereus contamination in the product found during stability testing at a 3rd party lab. <Read More> Methocarbamol Injection, USP 1000 mg/10 mL (100mg/mL) (Single Dose Vial) by Eugia US LLC (f/k/a AuroMedics Pharma LLC) – New Voluntary Recall – March 28, 2024 – Eugia US LLC (f/k/a AuroMedics Pharma LLC) has initiated a voluntary recall of lot number 3MC23011 of Methocarbamol Injection, USP 1000 mg/10 mL (100mg/mL) (Single Dose Vial) - 10mL Vial to the consumer level due to a customer product complaint for the presence of white particles floating inside of the vial. <Read More> Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL by Amneal Pharmaceuticals, LLC. – New Voluntary Recall – March 27, 2024 – Amneal Pharmaceuticals, LLC. Bridgewater, New Jersey (Amneal), is voluntarily recalling 4 lots (see table below) of Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5mL packaged in 80 mL, 150 mL, or 300 mL pack sizes, to the Consumer Level. Some bottles may have been overfilled which can result in an over potent dosing regimen. The recommended maximum daily dose allowance for this product is up to 2gm/day and patients prescribed a dosing regimen of 500 mg/10mL would exceed this daily allowance, which may be harmful to patients with renal insufficiency. The error occurred during the manual bottle filling stage of manufacturing. <Read More>
New Generic/Biosimilar Approval and Launch
No new update.
Clinical and Pharmacy News
Biden-Harris Administration Furthers Medicare Drug Price Negotiations, Releases New Data on How the President’s Historic Law Lowers Health Care Costs for Women – April 2, 2024 – The Inflation Reduction Act’s Medicare drug price negotiations and other provisions will lower the cost of prescription drugs for millions of women. The U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Planning and Evaluation (ASPE) released new research showing how key Inflation Reduction Act provisions will lower costs for women enrolled in Medicare, including nearly 30 million women enrolled in Part D. Also, HHS announced that the Centers for Medicare & Medicaid Services (CMS) responded to counteroffers from all manufacturers participating in Medicare drug price negotiations – which the Inflation Reduction Act made possible – and invited them to participate in further discussions. <Read More> Highly Pathogenic Avian Influenza A (H5N1) Virus Infection Reported in a Person in the U.S. – April 1, 2024 – A person in the United States has tested positive for highly pathogenic avian influenza (HPAI) A(H5N1) virus (“H5N1 bird flu”), as reported by Texas and confirmed by CDC. This person had exposure to dairy cattle in Texas presumed to be infected with HPAI A(H5N1) viruses. The patient reported eye redness (consistent with conjunctivitis), as their only symptom, and is recovering. The patient was told to isolate and is being treated with an antiviral drug for flu. This infection does not change the H5N1 bird flu human health risk assessment for the U.S. general public, which CDC considers to be low. <Read More> Study: ‘Gamechanger’ Diabetes Drugs Cost up to 400 Times More Than Needed – March 28, 2024 – Drug companies are pricing diabetes medicines at almost 400 times the level necessary to make a profit, according to a new study. Researchers said it would also be possible for modern insulin pens, which are safer and offer more accurate doses than vials and syringes, to be used even in low-income countries if pharmaceutical firms “put people before their astronomical profits”. A new generation of diabetes drugs known as GLP-1 receptor agonists (GLP-1s) include Novo Nordisk’s Ozempic® (semaglutide), taken by some celebrities as a weight-loss aid, and Eli Lilly’s Trulicity® (dulaglutide). They are now a standard part of treatment in high-income countries, but are unaffordable in many parts of the world despite rising rates of the condition. <Read More> ASCO Updates Guidelines on Vaccines in Patients with Cancer – March 27, 2024 – The American Society of Clinical Oncology (ASCO) recently issued a new clinical practice guideline, “Vaccinations of Adults with Cancer,” updating its recommendations for patients with cancer of which vaccines to receive. For adult patients of all ages, the guideline recommends: 1) Influenza vaccine annually, 2) COVID-19 vaccine according to the recommended CDC schedule, 3) Tdap or Td vaccine once, followed by a booster every 10 years, 4) Two doses of recombinant zoster vaccine at least 4 weeks apart, 5) One dose of PCV20 pneumococcal vaccine or 1 dose of PCV15 followed by PPSV23 8 weeks later. <Read More> The Truth About Compounded GLP-1s That Doctors Need to Know – March 26, 2024 – Meanwhile, the APC statement notes, Novo Nordisk and Eli Lilly have sued compounding companies in several states, questioning, among other things, the purity and potency of some compounded products. There are different designations for compounding pharmacies: 503A and 503B. 503As are state-licensed pharmacies and physicians, and 503B pharmacies are federally regulated outsourcing facilities that are strictly regulated by the FDA. This regulation, established following a 2012 fungal meningitis outbreak linked to a compounding pharmacy, ensures higher-quality control and oversight, especially for medications intended for intravenous or epidural use. These standards exceed those required for subcutaneous injections like GLP-1 analogs. <Read More> FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects – March 26, 2024 – The U.S. Food and Drug Administration is warning consumers not to use certain over-the-counter analgesic (pain relief) products that are marketed for topical use to relieve pain before, during or after certain cosmetic procedures, such as microdermabrasion, laser hair removal, tattooing and piercing. The agency issued warning letters to six companies for marketing these products in violation of federal law. Some of these products are labeled to contain ingredients, such as lidocaine, at concentrations that are higher than what is permitted for over-the-counter, topical pain relief products. <Read More>
340B in the News
Last Call for Comments on the Bipartisan Discussion Draft of the SUSTAIN Act: Shaping 340B for the Future. – March 26, 2024 – Only a few days remain for stakeholders—which includes drug manufacturers, patients, health care providers, pharmacies and others— to take advantage of a rare opportunity to influence the statutory contours of the 340B Drug Pricing Program (the “340B Program” or the “Program”). Specifically, industry stakeholders have until April 1st to submit comments to legislators regarding the Discussion Draft Explanatory Statement and Supplemental RFI (the “RFI”) of the “Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act” (the “Sustain 340B Act”). This bipartisan legislative discussion draft was released by the Senate 340B Working Group (the “Working Group”) earlier this year, to update the 340B Program. <Read More>
Clinical Insights: November 20, 2026
New Drug/Vaccine Approval
Pimjetmi® (pimicotinib) Capsules – New Drug Approval – November 10, 2026 – The Food and Drug Administration approved pimicotinib (Pimjetmi®, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. <Read More>
Sunharbo® (asundexian) Tablets – New Drug Approval – November 9, 2026 – Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Sunharbo® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIHSS ≤15) or high-risk transient ischemic attack (TIA). <Read More>
Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) Injection – New Drug Approval – October 30, 2026 – The U.S. Food and Drug Administration granted accelerated approval for Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP), a rare disease caused by human papillomavirus (HPV) that leads to the formation of small, wart-like growths in the patient’s airways. <Read More>
Hibsago® (bepirovirsen) Injection – New Drug Approval – October 20, 2026 – The U.S. Food and Drug Administration approved Hibsago® (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis. Hibsago® is the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B. <Read More>
Brytly™ (apraclonidine hydrochloride) Ophthalmic Solution – New Drug Approval – October 16, 2026 – The U.S. Food and Drug Administration approved a new nonprescription eye drop treatment, Brytly™, apraclonidine ophthalmic solution, 0.125%, for relief of eye redness due to minor irritations. This is the first nonprescription eye drop with apraclonidine. <Read More>
Hovilpri® (pritelivir) Tablets – New Drug Approval – October 9, 2026 – FDA has approved Hovilpri® (pritelivir) tablets for adults with weakened immune systems (i.e., immunocompromised patients) who have mucocutaneous lesions caused by herpes simplex virus (HSV) infection and have not responded to other therapies (acyclovir, valacyclovir, or famciclovir). Mucocutaneous lesions occur on skin or mucosal surfaces, such as lips, nostrils, eyes and genitals. <Read More>
Weltruza™ (olanzapine) Powder for Extended-Release Injectable Suspension – New Drug Approval – October 8, 2026 – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved Weltruza™ (olanzapine) for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. Weltruza™ clinical trial results demonstrated improvement in symptoms (PANSS), significant reduction in illness severity (CGI-S), as well as improvement in personal and social functioning (PSP). <Read More>
Emcitate® (tiratricol) Tablets for Oral Suspension – New Drug Approval – September 28, 2026 – The U.S. Food and Drug Administration approved Emcitate® (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. <Read More>
Juvmo™ (tavapadon) Tablets – New Drug Approval – September 25, 2026 - AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved Juvmo™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson’s disease, a progressive neurological disorder that affects millions of people worldwide. <Read More>
New Label Expansions
Rybrevant Faspro™ (amivantamab and hyaluronidase-lpuj) Injection – New Expanded Label – November 5, 2026 - Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Rybrevant Faspro™ (amivantamab and hyaluronidase-lpuj) (subcutaneous injection, 160 mg/2,000 units per mL) as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum‑based chemotherapy and an anti‑PD‑(L)1 antibody. <Read More>
Ilumya® (tildrakizumab-asmn) Injection – New Expanded Label – October 30, 2026 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associated companies) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Ilumya® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA). <Read More>
Talzenna® (talazoparib) Capsules – New Expanded Label – October 26, 2026 - Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has expanded approval of Talzenna® (talazoparib) in combination with Xtandi® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (PC) with homologous recombination repair (HRR) gene mutations, including both BRCA and non-BRCA mutations. <Read More>
Skyrizi® (risankizumab-rzaa) Injection – New Expanded Label – October 23, 2026 - AbbVie (NYSE: ABBV) announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for Skyrizi® (risankizumab-rzaa) for adults with moderately to severely active Crohn’s disease (CD). Patients now have the option to start Skyrizi® treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment. <Read More>
Awiqli® (insulin icodec-abae) Injection – New Expanded Label – October 23, 2026 - Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first once-weekly, long-acting basal insulin, as an adjunct to diet and exercise to improve glycemic control (blood sugar) in children 10 years of age and older with type 2 diabetes. This approval offers a once-weekly basal insulin treatment option, which reduces the frequency of weekly basal injections from seven to one per week. <Read More>
Ultomiris® (ravulizumab-cwvz) Injection – New Expanded Label – October 21, 2026 - Alexion, AstraZeneca Rare Disease’s Ultomiris® (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether Ultomiris® slows kidney function decline in patients with IgAN. <Read More>
Jemperli® (dostarlimab-gxly) Injection – New Expanded Label – October 19, 2026 - GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved Jemperli® (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway. <Read More>
Orladeyo® (berotralstat) Capsules and Oral Pellets – New Expanded Label – October 16, 2026 - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for use of the oral pellet formulation of once-daily Orladeyo® (berotralstat) for prophylactic therapy in adults and adolescents aged 12 years and older. The new 150 mg Orladeyo® pellet formulation provides an alternative administration option for adults and adolescents who may have difficulty swallowing, prefer not to take a capsule or choose to remain on a pellet formulation beyond age 12. <Read More>
Ryzumvi® (phentolamine mesylate) Ophthalmic Solution – New Expanded Label – October 16, 2026 - Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved Ryzumvi® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. Ryzumvi® is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use. <Read More>
Enspryng® (satralizumab-mwge) Injection – New Expanded Label – October 15, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED), providing patients with the first and only at-home subcutaneous treatment option. <Read More>
Zilbrysq® (zilucoplan) Injection – New Expanded Label – October 15, 2026 - UCB (Euronext Brussels: UCB), a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily, autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with Zilbrysq® (zilucoplan). The autoinjector is designed to help simplify self-administration of Zilbrysq®, offering patients another administration option and a more convenient treatment experience. <Read More>
Evoxac® (cevimeline hydrochloride) Capsules and Oral Solution – New Expanded Label – October 15, 2026 - Cosette Pharmaceuticals, Inc. (“Cosette”), a U.S.-based specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Evoxac® (cevimeline HCl) oral solution for the treatment of symptoms of dry mouth in adults with Sjögren’s disease. <Read More>
Anktiva® (nogapendekin alfa inbakicept-pmln) – New Expanded Label – October 14, 2026 - The U.S. Food and Drug Administration expanded the approved use of Anktiva® (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guérin (BCG), to include adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has not responded to BCG treatment. Anktiva® is the first FDA-approved treatment specifically for patients with BCG-unresponsive, high-grade papillary-only disease. <Read More>
Tecentriq® (atezolizumab) Injection – New Expanded Label – October 8, 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. <Read More>
Tukysa® (tucatinib) Tablets – New Expanded Label – October 7, 2026 - Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Tukysa® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. <Read More>
Rhapsido® (remibrutinib) Tablets – New Expanded Label – October 6, 2026 - Novartis announced that the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines. The approval represents an important advancement for people whose chronic hives and itch can be triggered by everyday skin friction, scratching, or rubbing. <Read More>
Jaypirca® (pirtobrutinib) Tablets – New Expanded Label – October 2, 2026 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This FDA action expands the Jaypirca label to include patients earlier in their treatment course and also converts the December 2023 accelerated approval for later-line CLL/SLL to a traditional approval. <Read More>
Camzyos® (mavacamten) Capsules – New Expanded Label – September 30, 2026 - Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved Camzyos® (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more. Camzyos® now has the broadest indication of any cardiac myosin inhibitor (CMI). <Read More>
Gazyva® (obinutuzumab) – New Expanded Label – September 25, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), has received U.S. Food and Drug Administration (FDA) approval of Gazyva® (obinutuzumab) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission. <Read More>
Olumiant® (baricitinib) Tablets – New Expanded Label – September 25, 2026 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Olumiant® (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe alopecia areata (AA). The approval expands Olumiant®’s U.S. label, building on its established use in adults with moderately to severely active rheumatoid arthritis and severe AA. AA is a chronic immune-mediated disease that causes unpredictable hair loss. <Read More>
Yusimry® (adalimumab-aqvh) Injection – New Expanded Label – September 25, 2026 - Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, announced that the U.S. Food and Drug Administration (“FDA”) has approved a high-concentration formulation (“HCF”) for Yusimry® (adalimumab-aqvh), as an interchangeable biosimilar to Humira. <Read More>
New Drug Shortage
November 16, 2026
Abacavir Sulfate Injection (Discontinuation)
Lamivudine Injection (Discontinuation)
Olipudase alfa-rpcp Injection (Currently in Shortage)
November 13, 2026
Bendamustine Hydrochloride Injection (Discontinuation)
Propranolol Hydrochloride Capsule, Extended Release (Discontinuation)
Somatropin Injection (Discontinuation)
Valrubicin Solution (Discontinuation)
November 6, 2026
Lincomycin Hydrochloride Injection (Discontinuation)
November 5, 2026
Tadalafil Tablet (Discontinuation)
October 30, 2026
Cefazolin in Dextrose Injection (Discontinuation)
Cefepime Hydrochloride Injection (Discontinuation)
Ceftriaxone Sodium Injection (Discontinuation)
Ciprofloxacin Hydrochloride and Hydrocortisone Otic Suspension/Drops (Discontinuation)
Updated Drug Shortage
November 13, 2026
Hydroxocobalamin Injection (Currently in Shortage)
November 10, 2026
Dextrose Monohydrate 10% Injection (Currently in Shortage)
Dextrose Monohydrate 5% Injection (Currently in Shortage)
Heparin Sodium Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Rocuronium Bromide Injection (Currently in Shortage)
November 9, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
Atropine Sulfate Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Carboplatin Injection (Currently in Shortage)
Dextrose Monohydrate 50% Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Etomidate Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Hydromorphone Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Lorazepam Injection (Currently in Shortage)
Methotrexate Sodium Injection (Currently in Shortage)
Midazolam Hydrochloride Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Pentostatin Injection (Currently in Shortage)
Sodium Bicarbonate Injection (Currently in Shortage)
Sufentanil Citrate Injection (Currently in Shortage)
November 6, 2026
Clindamycin Phosphate Injection (Currently in Shortage)
Dexmedetomidine Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
Rifampin Injection (Currently in Shortage)
November 4, 2026
Clonazepam Tablet (Resolved)
New Drug Recall and Safety Alerts
Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter – November 9, 2026 - Eugia US LLC (f/k/a Auro Medics Pharma LLC) is voluntarily recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) to the hospital/healthcare facility/user level due to the presence of particulate matter identified as a glass particle inside the vial. <Read More>
Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter – October 14, 2026 - Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel, that was detected in certain lots. <Read More>
Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter – October 9, 2026 - Par Health is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose. <Read More>
Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels – October 1, 2026 – Greenwich RxExternal Link Disclaimer, a 503A compounding pharmacy, is voluntarily recalling specific lots of its compounded glutathione to the consumer level. The product is being recalled due to potential elevated endotoxin levels. <Read More>
Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection – September 21, 2026 - Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% Sodium Chloride Injection, USP, 100mL single pack to the user level due to a potential mix-up. The affected lot of 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23 Lot 1042188) may potentially contain the overwrap with labeling indicating it to be 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23) but the actual product within the overwrap may be Potassium Chloride Inj. 10 mEq, (NDC 0990-7074-26) Lot 1035181. <Read More>
New Generic/Biosimilar Approval and Launch
Lucamzi™ (ranibizumab-blrz) Injection – New Lucentis® Biosimilar Approval – October 27, 2026 – Lucamzi™ (ranibizumab-blrz) biosimilar to Lucentis® has been approved by FDA in the US. Xbrane will finalize preparation for an upcoming launch of the product during 2027 together with its partners. <Read More>
Clinical and Pharmacy News
URGENT Notice to NCPDP Pharmacy Provider Members Using IINs (BINs) Recommendations to Address Risks with the Transition from the Six-Digit IIN (BIN) to Eight-Digit IIN (BIN) – This is a notification from the NCPDP Strategic National Implementation Process (SNIP) Committee to assist pharmacy provider stakeholders with the transition from the six-digit IIN (formerly known as BIN) to the eight-digit IIN. The compliance dates associated with several CMS final rules recently published set a more distinct timeline as to when various systems and processes should begin using the eight-digit IIN. Stakeholders are encouraged to review the information and recommendations below. Also reference other NCPDP resources to coordinate implementation timelines and mitigate transaction processing barriers. <Read More>
FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin – November 16, 2026 – Modifications to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) for isotretinoin officially took effect November 15, 2026, introducing changes intended to reduce administrative burdens for patients, prescribers, and pharmacies while maintaining safeguards against fetal exposure to the medication. <Read More>
WHO Issues First Guidelines on Type 1 Diabetes for Adults – November 14, 2026 – More than 100 years after the discovery of insulin, many people living with type 1 diabetes still cannot access the insulin and care they need to survive. Type 1 diabetes is a lifelong condition in which the body does not produce enough insulin, making people dependent on daily insulin to survive. Marking World Diabetes Day 2026, the World Health Organization (WHO) has issued its first guidelines on the diagnosis and management of type 1 diabetes in adults, with recommendations designed to apply across all settings, including low-resource, emergency and humanitarian settings. <Read More>
AHA 2026: Pharmacists at the Center of Cardiometabolic Care – November 13, 2026 - When the American Heart Association (AHA) Scientific Sessions 2026 convened in Chicago, Illinois, from November 6 to 9, 2026, the data spanned a new class of incretin-based therapy, longer-term results for the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, blood pressure effects of an oral glucagon-like peptide-1 (GLP-1) receptor agonist, and real-world models of heart failure (HF) care. Across Pharmacy Times interviews and abstract coverage from the meeting, a common theme emerged: pharmacists are increasingly central to how new cardiometabolic therapies are titrated, monitored, and sustained. <Read More>
DOL Finalizes Pharmacy Benefit Manager Fee Disclosure Rule: What PBMs Must Disclose, and Should be Ready to Defend – November 4, 2026 – Pharmacy benefit managers (PBMs) that serve large, self-insured health plans will have to give employers a detailed account of how they are paid under a rule the U.S. Department of Labor (DOL) finalized on October 29, 2026. Employers will also have the right to audit that information. PBMs have time to prepare but should not wait. A PBM that wants to rely on the 90-day advance-notice benchmark for renewals will need its disclosures ready well before the rule applies. <Read More>
How the Biosimilars Access and Affordability Act Redefines IRA Delays – November 3, 2026 - Congress is again weighing changes to how the Inflation Reduction Act (IRA) treats biologics facing imminent biosimilar competition. The Biosimilars Access and Affordability Act (H.R. 10628/S. 5571), reintroduced in both the House and Senate, would create clearer criteria for delaying Medicare price negotiation of a reference biologic when a biosimilar is expected to reach the market while keeping the IRA’s 2-year maximum delay. Under the bill, manufacturers would certify their expected launch information, and if the biosimilar is not licensed and marketed within the 2-year period, the reference biologic would enter negotiation, and its manufacturer would owe rebates covering the delayed years. <Read More>
340B in the News
Protecting the 340B Program Means Protecting Patients First – November 13, 2026 – Every month roughly 30 patients at Third Street Health Center in Ohio pick up their prescriptions for about $6. Beginning in January, some of those same prescriptions could cost them more than $500. That is what a new federal rebate pilot program means for community health centers, the providers that use the 340B Drug Pricing Program exactly as Congress intended. Plenty has been written about the abuse of 340B, but CHCs are model stewards of the program and are required to reinvest any savings back into patient care. <Read More>
340B Cuts Softened, Site-Neutral Expansion Progresses in CMS CY 2027 OPPS Final Rule – November 5, 2026 - CMS finalized 340B drug reimbursement at ASP minus 28%, less than the proposed 33.4% cut, while accelerating the annual recoupment offset to 2% through 2031. The agency will reimburse imaging without contrast at grandfathered off-campus hospital outpatient departments at the Physician Fee Schedule equivalent, setting the rate at 40% of the standard OPPS rate. Hospitals will receive a net 2.3% payment update that industry advocates criticize as insufficient, alongside the removal of 637 services from the Inpatient Only list. <Read More>
Medicare Will Cut Billions From 340B, Expand Site-Neutral Payments in 2027 – November 5, 2026 - Medicare will slash payment rates for a federal drug discount program and broaden site-neutral policies next year, according to a final rule released by the CMS on Wednesday. 340B payments are set to drop by billions of dollars and Medicare will pay the same amount for more medical procedures, regardless if they’re furnished in hospital-owned outpatient departments. Under the final rule, hospital outpatient departments and ASCs will also see their Medicare payments increase 2.3% next year, slightly less than the 2.4% bump regulators proposed in July. <Read More>
Pharmacy Benefit Managers Take Savings Intended for 340B Providers Serving Vulnerable Patients – November 4, 2026 – A “pharmacy benefit manager” is a kind of middleman company that administers prescription drug benefits for insurers and employers, managing formularies, negotiating manufacturer rebates, processing claims, and overseeing pharmacy networks…But here’s how PBMs can legally steal every day from 340B safety-net nonprofit providers that Congress intended to invest back in services for vulnerable populations. Through corporate vertical integration, PBMs such as CVS Health, Express Scripts, and OptumRx own or control pharmacies participating in 340B, allowing them to capture portions of the drug-discount margin. Five major PBMs control 75% of 340B contract-pharmacy relationships, while more than half of contract-pharmacy 340B savings are going to CVS, which owns Aetna; Cigna, which owns Express Scripts; and United Healthcare, which owns Optum Rx. <Read More>
CMS Finalizes Increases to Medicare Hospital Outpatient Department Payment Rates, Changes to Site-Neutral and 340B for 2027 – November 4, 2026 – The Centers for Medicare & Medicaid Services Nov. 4 issued a final rule that increases Medicare hospital outpatient prospective payment system rates by a net 2.3% in calendar year 2027 compared to 2026. This includes a 3.2% market basket update, offset by a 0.9 percentage point cut for productivity. In a statement shared with the media, Ashley Thompson, AHA senior vice president of public policy analysis and development, said, “CMS’ Medicare outpatient hospital payment rate does not adequately take into account the financial challenges facing hospitals today. These challenges are amplified for hospitals serving rural and underserved communities, many of which are already making hard decisions about how they will maintain access to healthcare services in their communities.” <Read More>
Understanding the Origins of the 340B Drug Pricing Program – October 29, 2026 – Although nearly half of all U.S. hospitals participate in it, few Americans have heard of the 340B Drug Pricing Program. The program was designed to allow health care providers that serve low-income and uninsured patients, such as federally qualified health centers (FQHCs), to buy drugs from manufacturers at significant discounts to offset losses from uncompensated care. However, the program has grown significantly over time to include more than 60,000 clinical sites and accounts for more than $100 billion in discounted spending. Because discounted drugs can be used for all patients — not just those who cannot pay — providers participating in the program can generate revenue from billing discounted drugs to payers, including Medicaid, Medicare, and private insurance. Critics of the program have raised questions regarding hospitals’ use of revenue from the program. <Read More>
Manufacturer Notices to 340B Covered Entities
Clinical Insights: November 20, 2026
New Drug/Vaccine Approval
Pimjetmi® (pimicotinib) Capsules – New Drug Approval – November 10, 2026 – The Food and Drug Administration approved pimicotinib (Pimjetmi®, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. <Read More>
Sunharbo® (asundexian) Tablets – New Drug Approval – November 9, 2026 – Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Sunharbo® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIHSS ≤15) or high-risk transient ischemic attack (TIA). <Read More>
Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) Injection – New Drug Approval – October 30, 2026 – The U.S. Food and Drug Administration granted accelerated approval for Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP), a rare disease caused by human papillomavirus (HPV) that leads to the formation of small, wart-like growths in the patient’s airways. <Read More>
Hibsago® (bepirovirsen) Injection – New Drug Approval – October 20, 2026 – The U.S. Food and Drug Administration approved Hibsago® (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis. Hibsago® is the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B. <Read More>
Brytly™ (apraclonidine hydrochloride) Ophthalmic Solution – New Drug Approval – October 16, 2026 – The U.S. Food and Drug Administration approved a new nonprescription eye drop treatment, Brytly™, apraclonidine ophthalmic solution, 0.125%, for relief of eye redness due to minor irritations. This is the first nonprescription eye drop with apraclonidine. <Read More>
Hovilpri® (pritelivir) Tablets – New Drug Approval – October 9, 2026 – FDA has approved Hovilpri® (pritelivir) tablets for adults with weakened immune systems (i.e., immunocompromised patients) who have mucocutaneous lesions caused by herpes simplex virus (HSV) infection and have not responded to other therapies (acyclovir, valacyclovir, or famciclovir). Mucocutaneous lesions occur on skin or mucosal surfaces, such as lips, nostrils, eyes and genitals. <Read More>
Weltruza™ (olanzapine) Powder for Extended-Release Injectable Suspension – New Drug Approval – October 8, 2026 – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved Weltruza™ (olanzapine) for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. Weltruza™ clinical trial results demonstrated improvement in symptoms (PANSS), significant reduction in illness severity (CGI-S), as well as improvement in personal and social functioning (PSP). <Read More>
Emcitate® (tiratricol) Tablets for Oral Suspension – New Drug Approval – September 28, 2026 – The U.S. Food and Drug Administration approved Emcitate® (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. <Read More>
Juvmo™ (tavapadon) Tablets – New Drug Approval – September 25, 2026 - AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved Juvmo™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson’s disease, a progressive neurological disorder that affects millions of people worldwide. <Read More>
New Label Expansions
Rybrevant Faspro™ (amivantamab and hyaluronidase-lpuj) Injection – New Expanded Label – November 5, 2026 - Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Rybrevant Faspro™ (amivantamab and hyaluronidase-lpuj) (subcutaneous injection, 160 mg/2,000 units per mL) as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum‑based chemotherapy and an anti‑PD‑(L)1 antibody. <Read More>
Ilumya® (tildrakizumab-asmn) Injection – New Expanded Label – October 30, 2026 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associated companies) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Ilumya® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA). <Read More>
Talzenna® (talazoparib) Capsules – New Expanded Label – October 26, 2026 - Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has expanded approval of Talzenna® (talazoparib) in combination with Xtandi® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (PC) with homologous recombination repair (HRR) gene mutations, including both BRCA and non-BRCA mutations. <Read More>
Skyrizi® (risankizumab-rzaa) Injection – New Expanded Label – October 23, 2026 - AbbVie (NYSE: ABBV) announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for Skyrizi® (risankizumab-rzaa) for adults with moderately to severely active Crohn’s disease (CD). Patients now have the option to start Skyrizi® treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment. <Read More>
Awiqli® (insulin icodec-abae) Injection – New Expanded Label – October 23, 2026 - Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first once-weekly, long-acting basal insulin, as an adjunct to diet and exercise to improve glycemic control (blood sugar) in children 10 years of age and older with type 2 diabetes. This approval offers a once-weekly basal insulin treatment option, which reduces the frequency of weekly basal injections from seven to one per week. <Read More>
Ultomiris® (ravulizumab-cwvz) Injection – New Expanded Label – October 21, 2026 - Alexion, AstraZeneca Rare Disease’s Ultomiris® (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether Ultomiris® slows kidney function decline in patients with IgAN. <Read More>
Jemperli® (dostarlimab-gxly) Injection – New Expanded Label – October 19, 2026 - GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved Jemperli® (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway. <Read More>
Orladeyo® (berotralstat) Capsules and Oral Pellets – New Expanded Label – October 16, 2026 - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for use of the oral pellet formulation of once-daily Orladeyo® (berotralstat) for prophylactic therapy in adults and adolescents aged 12 years and older. The new 150 mg Orladeyo® pellet formulation provides an alternative administration option for adults and adolescents who may have difficulty swallowing, prefer not to take a capsule or choose to remain on a pellet formulation beyond age 12. <Read More>
Ryzumvi® (phentolamine mesylate) Ophthalmic Solution – New Expanded Label – October 16, 2026 - Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved Ryzumvi® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. Ryzumvi® is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use. <Read More>
Enspryng® (satralizumab-mwge) Injection – New Expanded Label – October 15, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED), providing patients with the first and only at-home subcutaneous treatment option. <Read More>
Zilbrysq® (zilucoplan) Injection – New Expanded Label – October 15, 2026 - UCB (Euronext Brussels: UCB), a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily, autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with Zilbrysq® (zilucoplan). The autoinjector is designed to help simplify self-administration of Zilbrysq®, offering patients another administration option and a more convenient treatment experience. <Read More>
Evoxac® (cevimeline hydrochloride) Capsules and Oral Solution – New Expanded Label – October 15, 2026 - Cosette Pharmaceuticals, Inc. (“Cosette”), a U.S.-based specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Evoxac® (cevimeline HCl) oral solution for the treatment of symptoms of dry mouth in adults with Sjögren’s disease. <Read More>
Anktiva® (nogapendekin alfa inbakicept-pmln) – New Expanded Label – October 14, 2026 - The U.S. Food and Drug Administration expanded the approved use of Anktiva® (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guérin (BCG), to include adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has not responded to BCG treatment. Anktiva® is the first FDA-approved treatment specifically for patients with BCG-unresponsive, high-grade papillary-only disease. <Read More>
Tecentriq® (atezolizumab) Injection – New Expanded Label – October 8, 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. <Read More>
Tukysa® (tucatinib) Tablets – New Expanded Label – October 7, 2026 - Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Tukysa® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. <Read More>
Rhapsido® (remibrutinib) Tablets – New Expanded Label – October 6, 2026 - Novartis announced that the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines. The approval represents an important advancement for people whose chronic hives and itch can be triggered by everyday skin friction, scratching, or rubbing. <Read More>
Jaypirca® (pirtobrutinib) Tablets – New Expanded Label – October 2, 2026 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This FDA action expands the Jaypirca label to include patients earlier in their treatment course and also converts the December 2023 accelerated approval for later-line CLL/SLL to a traditional approval. <Read More>
Camzyos® (mavacamten) Capsules – New Expanded Label – September 30, 2026 - Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved Camzyos® (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more. Camzyos® now has the broadest indication of any cardiac myosin inhibitor (CMI). <Read More>
Gazyva® (obinutuzumab) – New Expanded Label – September 25, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), has received U.S. Food and Drug Administration (FDA) approval of Gazyva® (obinutuzumab) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission. <Read More>
Olumiant® (baricitinib) Tablets – New Expanded Label – September 25, 2026 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Olumiant® (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe alopecia areata (AA). The approval expands Olumiant®’s U.S. label, building on its established use in adults with moderately to severely active rheumatoid arthritis and severe AA. AA is a chronic immune-mediated disease that causes unpredictable hair loss. <Read More>
Yusimry® (adalimumab-aqvh) Injection – New Expanded Label – September 25, 2026 - Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, announced that the U.S. Food and Drug Administration (“FDA”) has approved a high-concentration formulation (“HCF”) for Yusimry® (adalimumab-aqvh), as an interchangeable biosimilar to Humira. <Read More>
New Drug Shortage
November 16, 2026
Abacavir Sulfate Injection (Discontinuation)
Lamivudine Injection (Discontinuation)
Olipudase alfa-rpcp Injection (Currently in Shortage)
November 13, 2026
Bendamustine Hydrochloride Injection (Discontinuation)
Propranolol Hydrochloride Capsule, Extended Release (Discontinuation)
Somatropin Injection (Discontinuation)
Valrubicin Solution (Discontinuation)
November 6, 2026
Lincomycin Hydrochloride Injection (Discontinuation)
November 5, 2026
Tadalafil Tablet (Discontinuation)
October 30, 2026
Cefazolin in Dextrose Injection (Discontinuation)
Cefepime Hydrochloride Injection (Discontinuation)
Ceftriaxone Sodium Injection (Discontinuation)
Ciprofloxacin Hydrochloride and Hydrocortisone Otic Suspension/Drops (Discontinuation)
Updated Drug Shortage
November 13, 2026
Hydroxocobalamin Injection (Currently in Shortage)
November 10, 2026
Dextrose Monohydrate 10% Injection (Currently in Shortage)
Dextrose Monohydrate 5% Injection (Currently in Shortage)
Heparin Sodium Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Rocuronium Bromide Injection (Currently in Shortage)
November 9, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
Atropine Sulfate Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Carboplatin Injection (Currently in Shortage)
Dextrose Monohydrate 50% Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Etomidate Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Hydromorphone Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Lorazepam Injection (Currently in Shortage)
Methotrexate Sodium Injection (Currently in Shortage)
Midazolam Hydrochloride Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Pentostatin Injection (Currently in Shortage)
Sodium Bicarbonate Injection (Currently in Shortage)
Sufentanil Citrate Injection (Currently in Shortage)
November 6, 2026
Clindamycin Phosphate Injection (Currently in Shortage)
Dexmedetomidine Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
Rifampin Injection (Currently in Shortage)
November 4, 2026
Clonazepam Tablet (Resolved)
New Drug Recall and Safety Alerts
Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter – November 9, 2026 - Eugia US LLC (f/k/a Auro Medics Pharma LLC) is voluntarily recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) to the hospital/healthcare facility/user level due to the presence of particulate matter identified as a glass particle inside the vial. <Read More>
Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter – October 14, 2026 - Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel, that was detected in certain lots. <Read More>
Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter – October 9, 2026 - Par Health is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose. <Read More>
Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels – October 1, 2026 – Greenwich RxExternal Link Disclaimer, a 503A compounding pharmacy, is voluntarily recalling specific lots of its compounded glutathione to the consumer level. The product is being recalled due to potential elevated endotoxin levels. <Read More>
Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection – September 21, 2026 - Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% Sodium Chloride Injection, USP, 100mL single pack to the user level due to a potential mix-up. The affected lot of 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23 Lot 1042188) may potentially contain the overwrap with labeling indicating it to be 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23) but the actual product within the overwrap may be Potassium Chloride Inj. 10 mEq, (NDC 0990-7074-26) Lot 1035181. <Read More>
New Generic/Biosimilar Approval and Launch
Lucamzi™ (ranibizumab-blrz) Injection – New Lucentis® Biosimilar Approval – October 27, 2026 – Lucamzi™ (ranibizumab-blrz) biosimilar to Lucentis® has been approved by FDA in the US. Xbrane will finalize preparation for an upcoming launch of the product during 2027 together with its partners. <Read More>
Clinical and Pharmacy News
URGENT Notice to NCPDP Pharmacy Provider Members Using IINs (BINs) Recommendations to Address Risks with the Transition from the Six-Digit IIN (BIN) to Eight-Digit IIN (BIN) – This is a notification from the NCPDP Strategic National Implementation Process (SNIP) Committee to assist pharmacy provider stakeholders with the transition from the six-digit IIN (formerly known as BIN) to the eight-digit IIN. The compliance dates associated with several CMS final rules recently published set a more distinct timeline as to when various systems and processes should begin using the eight-digit IIN. Stakeholders are encouraged to review the information and recommendations below. Also reference other NCPDP resources to coordinate implementation timelines and mitigate transaction processing barriers. <Read More>
FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin – November 16, 2026 – Modifications to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) for isotretinoin officially took effect November 15, 2026, introducing changes intended to reduce administrative burdens for patients, prescribers, and pharmacies while maintaining safeguards against fetal exposure to the medication. <Read More>
WHO Issues First Guidelines on Type 1 Diabetes for Adults – November 14, 2026 – More than 100 years after the discovery of insulin, many people living with type 1 diabetes still cannot access the insulin and care they need to survive. Type 1 diabetes is a lifelong condition in which the body does not produce enough insulin, making people dependent on daily insulin to survive. Marking World Diabetes Day 2026, the World Health Organization (WHO) has issued its first guidelines on the diagnosis and management of type 1 diabetes in adults, with recommendations designed to apply across all settings, including low-resource, emergency and humanitarian settings. <Read More>
AHA 2026: Pharmacists at the Center of Cardiometabolic Care – November 13, 2026 - When the American Heart Association (AHA) Scientific Sessions 2026 convened in Chicago, Illinois, from November 6 to 9, 2026, the data spanned a new class of incretin-based therapy, longer-term results for the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, blood pressure effects of an oral glucagon-like peptide-1 (GLP-1) receptor agonist, and real-world models of heart failure (HF) care. Across Pharmacy Times interviews and abstract coverage from the meeting, a common theme emerged: pharmacists are increasingly central to how new cardiometabolic therapies are titrated, monitored, and sustained. <Read More>
DOL Finalizes Pharmacy Benefit Manager Fee Disclosure Rule: What PBMs Must Disclose, and Should be Ready to Defend – November 4, 2026 – Pharmacy benefit managers (PBMs) that serve large, self-insured health plans will have to give employers a detailed account of how they are paid under a rule the U.S. Department of Labor (DOL) finalized on October 29, 2026. Employers will also have the right to audit that information. PBMs have time to prepare but should not wait. A PBM that wants to rely on the 90-day advance-notice benchmark for renewals will need its disclosures ready well before the rule applies. <Read More>
How the Biosimilars Access and Affordability Act Redefines IRA Delays – November 3, 2026 - Congress is again weighing changes to how the Inflation Reduction Act (IRA) treats biologics facing imminent biosimilar competition. The Biosimilars Access and Affordability Act (H.R. 10628/S. 5571), reintroduced in both the House and Senate, would create clearer criteria for delaying Medicare price negotiation of a reference biologic when a biosimilar is expected to reach the market while keeping the IRA’s 2-year maximum delay. Under the bill, manufacturers would certify their expected launch information, and if the biosimilar is not licensed and marketed within the 2-year period, the reference biologic would enter negotiation, and its manufacturer would owe rebates covering the delayed years. <Read More>
340B in the News
Protecting the 340B Program Means Protecting Patients First – November 13, 2026 – Every month roughly 30 patients at Third Street Health Center in Ohio pick up their prescriptions for about $6. Beginning in January, some of those same prescriptions could cost them more than $500. That is what a new federal rebate pilot program means for community health centers, the providers that use the 340B Drug Pricing Program exactly as Congress intended. Plenty has been written about the abuse of 340B, but CHCs are model stewards of the program and are required to reinvest any savings back into patient care. <Read More>
340B Cuts Softened, Site-Neutral Expansion Progresses in CMS CY 2027 OPPS Final Rule – November 5, 2026 - CMS finalized 340B drug reimbursement at ASP minus 28%, less than the proposed 33.4% cut, while accelerating the annual recoupment offset to 2% through 2031. The agency will reimburse imaging without contrast at grandfathered off-campus hospital outpatient departments at the Physician Fee Schedule equivalent, setting the rate at 40% of the standard OPPS rate. Hospitals will receive a net 2.3% payment update that industry advocates criticize as insufficient, alongside the removal of 637 services from the Inpatient Only list. <Read More>
Medicare Will Cut Billions From 340B, Expand Site-Neutral Payments in 2027 – November 5, 2026 - Medicare will slash payment rates for a federal drug discount program and broaden site-neutral policies next year, according to a final rule released by the CMS on Wednesday. 340B payments are set to drop by billions of dollars and Medicare will pay the same amount for more medical procedures, regardless if they’re furnished in hospital-owned outpatient departments. Under the final rule, hospital outpatient departments and ASCs will also see their Medicare payments increase 2.3% next year, slightly less than the 2.4% bump regulators proposed in July. <Read More>
Pharmacy Benefit Managers Take Savings Intended for 340B Providers Serving Vulnerable Patients – November 4, 2026 – A “pharmacy benefit manager” is a kind of middleman company that administers prescription drug benefits for insurers and employers, managing formularies, negotiating manufacturer rebates, processing claims, and overseeing pharmacy networks…But here’s how PBMs can legally steal every day from 340B safety-net nonprofit providers that Congress intended to invest back in services for vulnerable populations. Through corporate vertical integration, PBMs such as CVS Health, Express Scripts, and OptumRx own or control pharmacies participating in 340B, allowing them to capture portions of the drug-discount margin. Five major PBMs control 75% of 340B contract-pharmacy relationships, while more than half of contract-pharmacy 340B savings are going to CVS, which owns Aetna; Cigna, which owns Express Scripts; and United Healthcare, which owns Optum Rx. <Read More>
CMS Finalizes Increases to Medicare Hospital Outpatient Department Payment Rates, Changes to Site-Neutral and 340B for 2027 – November 4, 2026 – The Centers for Medicare & Medicaid Services Nov. 4 issued a final rule that increases Medicare hospital outpatient prospective payment system rates by a net 2.3% in calendar year 2027 compared to 2026. This includes a 3.2% market basket update, offset by a 0.9 percentage point cut for productivity. In a statement shared with the media, Ashley Thompson, AHA senior vice president of public policy analysis and development, said, “CMS’ Medicare outpatient hospital payment rate does not adequately take into account the financial challenges facing hospitals today. These challenges are amplified for hospitals serving rural and underserved communities, many of which are already making hard decisions about how they will maintain access to healthcare services in their communities.” <Read More>
Understanding the Origins of the 340B Drug Pricing Program – October 29, 2026 – Although nearly half of all U.S. hospitals participate in it, few Americans have heard of the 340B Drug Pricing Program. The program was designed to allow health care providers that serve low-income and uninsured patients, such as federally qualified health centers (FQHCs), to buy drugs from manufacturers at significant discounts to offset losses from uncompensated care. However, the program has grown significantly over time to include more than 60,000 clinical sites and accounts for more than $100 billion in discounted spending. Because discounted drugs can be used for all patients — not just those who cannot pay — providers participating in the program can generate revenue from billing discounted drugs to payers, including Medicaid, Medicare, and private insurance. Critics of the program have raised questions regarding hospitals’ use of revenue from the program. <Read More>
Manufacturer Notices to 340B Covered Entities
Clinical Insights: October 1, 2026
New Drug/Vaccine Approval
Atebrioz™ (zilurgisertib) Tablets – New Drug Approval – September 25, 2026 – The U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (bone formation outside the skeleton) in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended starting dosage is 100 mg orally once daily with or without food. <Read More>
Onswik™ (insulin efsitora alfa-gobe) Injection - New Drug Approval – September 24, 2026 – Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin, indicated along with diet and exercise to control high blood sugar in adults with type 2 diabetes. Onswik™ is designed to deliver steady basal insulin levels over a full seven days. <Read More>
Lyrfigtu™ (lirafugratinib) Capsules – New Drug Approval – September 23, 2026 – The Food and Drug Administration approved lirafugratinib (Lyrfigtu™, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement. <Read More>
Fayuvi™ (rebisufligene etisparvovec-hopf) Suspension for Intravenous Infusion - formerly UX111 – New Drug Approval – September 17, 2026 – The U.S. Food and Drug Administration approved Fayuvi™ (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A., MPS IIIA is a rare inherited disease that progressively damages the brain and nervous system, causing children to lose cognitive, language and other developmental abilities over time. Until now, treatment was limited to managing symptoms; there was no FDA-approved therapy designed to change the underlying course of the disease. <Read More>
Bexlutry™ (lutetium Lu 177 dotatate) Injection – New Drug Approval – September 14, 2026 – Curium™ announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Bexlutry™ lutetium Lu 177 dotatate injection for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. <Read More>
Pixclara® (floretyrosine F 18) Injection – New Drug Approval – September 11, 2026 – Telix announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer). <Read More>
Isembyld™ (apitegromab-mstn) Injection – New Drug Approval – September 11, 2026 – Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, announced that the FDA has approved Isembyld™ (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. <Read More>
Etcamah™ (camizestrant) Tablets – New Drug Approval – September 4, 2026 – The Food and Drug Administration granted accelerated approval to camizestrant (Etcamah™, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test. <Read More>
Zanvastro™ (zilganersen) Injection – New Drug Approval – September 3, 2026 – The U.S. Food and Drug Administration has approved Zanvastro™ (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients. Zanvastro™ is the first FDA-approved treatment for Alexander disease and the first therapy to directly target the protein buildup that drives the disease. <Read More>
Omcazio™ (cabozantinib) Capsules – New Drug Approval – September 3, 2026 – Handa Pharmaceuticals, Inc. (“Handa” or the “Company”) (TSE:6620) announced that the U.S. Food and Drug Administration (“FDA”) has granted final approval to Omcazio™ (cabozantinib) capsules, the lauryl sulfate salt formulation of cabozantinib developed by the Company’s U.S. subsidiary, Handa Oncology, LLC. The action converts Handa’s prior tentative approval to final approval and authorizes Omcazio™ for commercialization in the United States. <Read More>
Mimrylo™ (rusfertide) Lyophilized Powder for Injection – New Drug Approval – August 28, 2026 – Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for Mimrylo™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. <Read More>
Bixlenvo™ (bictegravir and lenacapavir) Tablets – New Drug Approval – August 27, 2026 – Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo™ is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs. <Read More>
Lisraya™ (brepocitinib) Tablets – New Drug Approval – August 27, 2026 - The U.S. Food and Drug Administration has approved Lisraya™ (brepocitinib) tablets for the treatment of dermatomyositis in adults. For decades, dermatomyositis patients have had limited treatment options to manage their symptoms. The approval of Lisraya™ offers patients an important new alternative by providing an effective oral treatment option. <Read More>
Rasonque™ (daraxonrasib) Tablets – New Drug Approval – August 26, 2026 – The U.S. Food and Drug Administration approved Rasonque™ (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. <Read More>
New Label Expansions
Welireg® (belzutifan) Tablets – New Expanded Label – September 24, 2026 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced the U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of Welireg® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus Lenvima® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. <Read More>
Aqneursa® (levacetylleucine) Granules for Oral Suspension – New Expanded Label – September 18, 2026 – The U.S. Food and Drug Administration has approved Aqneursa® (levacetylleucine) for oral suspension to treat ataxia in adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg (about 33 pounds). Aqneursa® was previously approved in 2024 to treat the neurological manifestations of Niemann-Pick disease type C. This approval makes Aqneursa® the first treatment approved for ataxia in patients with ataxia-telangiectasia. <Read More>
Kerendia® (finerenone) Tablets – New Expanded Label – September 17, 2026 – Bayer announced that the U.S. Food and Drug Administration (FDA) approved Kerendia® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), following the agency’s Priority Review of the supplemental New Drug Application (sNDA). <Read More>
Ibtrozi® (taletrectinib) Capsules – New Expanded Label – September 16, 2026 – Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Ibtrozi® (taletrectinib), a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). <Read More>
Inluriyo® (imlunestrant) Tablets – New Expanded Label – September 16, 2026 – Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Inluriyo® (imlunestrant), an oral estrogen receptor (ER) antagonist, in combination with Verzenio® (abemaciclib), a CDK4/6 inhibitor, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated locally advanced or metastatic breast cancer (MBC), as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Joenja® (leniolisib) Tablets – New Expanded Label – September 11, 2026 – FDA has approved Joenja® (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children 4-11 years who weigh at least 27 kg. Joenja® was first approved in 2023 for the same indication in patients 12 years and older at a dose of 70 mg orally twice a day. Children 4-11 years take a weight-based dosage (40, 50, or 70 mg) orally twice a day, approximately 12 hours apart. <Read More>
Imdelltra® (tarlatamab-dlle) for Injection – New Expanded Label – September 11, 2026 – Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved an update to the Imdelltra® (tarlatamab-dlle) Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in an appropriate healthcare setting. This approval means that patients receiving Imdelltra® should now be monitored for 6 to 8 hours from the start of their first two infusions, compared with the previously recommended 22 to 24 hours. <Read More>
Ameluz® (aminolevulinic acid) Gel – New Expanded Label – September 9, 2026 – Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED® lamp series, for the treatment of superficial Basal Cell Carcinoma (sBCC) in adults. <Read More>
Hyrnuo® (sevabertinib) Tablets – New Expanded Label – September 9, 2026 – The Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo®, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. <Read More>
Stelara® (ustekinumab) Injection – New Expanded Label – August 28, 2026 – The U.S. Food and Drug Administration has approved Stelara® (ustekinumab) injection for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients aged 2 years old and older. On April 15, 2026, Stelara® was approved for the treatment of moderately to severely active Crohn’s disease (CD) in pediatric patients aged 2 years old and older. Stelara® is the first approved therapeutic monoclonal antibody that does not target human tumor necrosis factor alpha (TNFα) for the two main forms of pediatric inflammatory bowel disease. <Read More>
Besremi® (ropeginterferon alfa-2b-njft) Injection – New Expanded Label – August 28, 2026 – PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446) announced the U.S. Food and Drug Administration (FDA) has approved Besremi® (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), making it the first new FDA-approved treatment for ET in nearly three decades. Besremi® has been approved for adults with ET, regardless of their genotype or disease status, including newly diagnosed patients who are naive to cytoreductive therapy. <Read More>
Spikevax® (COVID-19 Vaccine, mRNA) Injection – New Expanded Label – August 27, 2026 – Moderna, Inc. (NASDAQ:MRNA) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19. <Read More>
Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted) Injectable Suspension – August 27, 2026 – Novavax, Inc.'s (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan. These approvals position Novavax to continue earning royalties on net sales in these markets this season. <Read More>
Comirnaty® (COVID-19 Vaccine, mRNA) Injection – New Expanded Label – August 27, 2026 – Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (Comirnaty® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. <Read More>
Mounjaro® (tirzepatide) Injection – New Expanded Label – August 27, 2026 – Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro® (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. <Read More>
Tevimbra® (tislelizumab-jsgr) Injection – New Expanded Label – August 25, 2026 – BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Tevimbra® (tislelizumab) in combination with Ziihera® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). <Read More>
New Drug Shortage
September 21, 2026
Arsenic Trioxide Injection (Discontinuation)
September 18, 2026
Rivaroxaban For Suspension (Discontinuation)
Rivastigmine Film, Extended Release (Discontinuation)
September 16, 2026
Melphalan Hydrochloride Injection (Discontinuation)
Mesalamine Capsule, Extended Release (Discontinuation)
September 11, 2026
Cisatracurium Besylate Injection (Discontinuation)
Micafungin Sodium Injection (Discontinuation)
September 10, 2026
Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution (Discontinuation)
Updated Drug Shortage
September 22, 2026
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Carboplatin Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Heparin Sodium Injection (Currently in Shortage)
Hydromorphone Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Lorazepam Injection (Currently in Shortage)
Midazolam Hydrochloride Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Sodium Bicarbonate Injection (Currently in Shortage)
September 21, 2026
Clindamycin Phosphate Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
September 18, 2026
Bumetanide Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Oral Solution (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lisdexamfetamine Dimesylate Capsule (Currently in Shortage)
Lisdexamfetamine Dimesylate Tablet, Chewable (Currently in Shortage)
Methotrexate Sodium Injection (Currently in Shortage)
Methylphenidate Hydrochloride Tablet, Extended Release (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Promethazine Hydrochloride Injection (Currently in Shortage)
Technetium TC-99M Pyrophosphate Kit Injection (Currently in Shortage)
September 17, 2026
Carboplatin Injection (Currently in Shortage)
Clindamycin Phosphate Injection (Currently in Shortage)
Dextrose Monohydrate 10% Injection (Currently in Shortage)
Dextrose Monohydrate 5% Injection (Currently in Shortage)
Dextrose Monohydrate 70% Injection (Currently in Shortage)
Ifosfamide Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
September 16, 2026
Desmopressin Acetate Spray (Currently in Shortage)
Lisdexamfetamine Dimesylate Capsule (Currently in Shortage)
Streptozocin Powder, For Solution (Currently in Shortage)
New Drug Recall and Safety Alerts
Par Health Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection – September 18, 2026 - Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose or stopper material. <Read More>
Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP – September 17, 2026 - Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% Sodium Chloride Injection, USP, 100mL single pack to the user level due to a potential mix-up. The affected lot of 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23 Lot 1042188) may potentially contain the overwrap with labeling indicating it to be 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23) but the actual product within the overwrap may be Potassium Chloride Inj. 10 mEq, (NDC 0990-7074-26) Lot 1035181. <Read More>
B. Braun Medical Inc. Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container – September 3, 2026 - B. Braun Medical Inc (B. Braun) is voluntarily recalling three (3) lots of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container, to the hospital/healthcare facility/user level due to presence of particulate matter identified as iron oxide, inorganic, cellulose or polystyrene particulate matter. <Read More>
Baxter Issues Voluntary Nationwide Recall for Two Lots of 0.9% Sodium Chloride Injection – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling two lots of 0.9% Sodium Chloride Injection due to the potential presence of particulate matter identified as fiberglass in the solution. <Read More>
Baxter Issues Voluntary Nationwide Recall for One Lot of Anticoagulant Sodium Citrate Solution – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of Anticoagulant Sodium Citrate Solution due to the potential presence of particulate matter identified as fiberglass in the solution. <Read More>
Baxter Issues Voluntary Nationwide Recall for One Lot of 70% Dextrose Injection – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of 70% Dextrose Injection due to the potential presence of particulate matter identified as stainless steel particles in the solution. <Read More>
New Generic/Biosimilar Approval and Launch
Bravnetsa™ (lutetium Lu 177 dotatate) Injection – New Lutathera® Biosimilar Approval – September 21, 2026 – Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Bravnetsa™ (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to Lutathera® (lutetium Lu 177 dotatate). <Read More>
Clinical and Pharmacy News
Navigating GLP-1 Switches: A Guide for Primary Care – September 29, 2026 - As GLP-1 receptor agonists and dual incretin agents become more common in treating obesity and type 2 diabetes, primary care providers are handling more medication switches. The reason may be insurance coverage, ongoing gastrointestinal side effects, inadequate response, or the need for better blood sugar control or weight support. Whatever the driver, switching is not simply trading one prescription for another. It requires planning around half-lives, dose history, side effects, and the risk for blood sugar swings. <Read More>
Insurance Coverage Lags as Cancer Science, Treatment Move Forward – September 24, 2026 - Eighteen months after his initial diagnosis, chemotherapy hadn’t slowed 21-year-old Mason Henderson’s rare brain tumor, which had spread to his spinal fluid. So, he left his home in southeastern Texas to spend three weeks in a clinical trial in New York City. But that failed, too, leaving a murky path for Henderson, whose cancer was so rare the World Health Organization had only given it a name in 2021. So early this year, Henderson’s doctors, evaluating his tumor’s deep genetic language, turned to a drug made by Merck and AstraZeneca called Lynparza®. <Read More>
Cholesterol Control Gets Personalized—How New Guidelines Tailor Treatment to Your Unique Risk Profile – September 24, 2026 – As a cardiologist with expertise in sports and exercise science, I routinely care for patients who want to make healthy lifestyle choices to control their cholesterol levels, reduce their risk of cardiovascular disease and improve their overall health. In March 2026, the American Heart Association and the American College of Cardiology issued new guidelines on how to treat dyslipidemia. The guidelines, last updated in 2018, incorporate findings from several new studies on how to more effectively treat—and prevent—the condition. The new guidelines can help doctors personalize treatment to reduce each patient's risk of developing cardiovascular disease. <Read More>
VA/DoD Release Updated Tobacco Cessation Clinical Practice Guidelines – September 22, 2026 - The US Department of Veterans Affairs (VA) and Department of Defense (DoD) have released an updated clinical practice guideline recommending varenicline or combination nicotine replacement therapy as the preferred treatments for tobacco cessation, according to a synopsis published in Annals of Internal Medicine. The updated guidance addresses nicotine and tobacco use among service members and veterans, noting that use leads to adverse physical and mental health effects, and reduces military force readiness. For respiratory therapists and allied healthcare professionals treating patients with chronic lung conditions and nicotine dependence, the document outlines practical strategies to improve long-term abstinence rates. <Read More>
Generic Drug Costs Burdening Patients as Much as Brand Name Options – September 18, 2026 - Aggregate OOP burden for generics exceeds brands due to utilization intensity, especially among Medicare beneficiaries with higher generic fill counts and near-parity annual OOP spending versus brands. Cost-related nonadherence remains substantial, with reported treatment abandonment and dose modification, positioning community pharmacists as key actors in mitigating downstream acute-care utilization. <Read More>
Specialty Pharmacy Leaders to Convene for NASP inSPire2026 – September 18, 2026 - As specialty pharmacy addresses the rising cost and complexity of cell and gene therapies, this year's newly rebranded inSPire2026 meeting will bring pharmacists, nurses, and industry leaders together to chart how those breakthroughs actually reach patients. From September 22 to 25, 2026, specialty pharmacy professionals gathered for inSPire2026, the newly rebranded successor to the National Association of Specialty Pharmacy's (NASP) Annual Meeting & Expo. <Read More>
340B in the News
340B Hospitals Lag Behind Peers in Charity Care Spending: Report – September 25, 2026 - A new report from a conservative think tank is accusing 340B hospitals of providing less charity care than other nonprofit hospitals, despite receiving discounted drugs. Hospitals participating in the 340B drug discount program spent 2.16% of their operating expenses on free or discounted care for low-income patients, called charity care, compared with 2.82% at non-340B hospitals, according to a Thursday analysis from the Pioneer Institute and CancerCare. <Read More>
What the Revised 340B Rebate Pilot Programme Means for Pharma Revenue Operations – September 24, 2026 - The US government's revised 340B rebate pilot programme signals that pharmaceutical manufacturers need to prepare their operations for the next phase of drug discount management. The pilot shifts how pharmaceutical manufacturers provide 340B discounts to eligible hospitals and healthcare providers. The savings for certain medications will now come in the form of rebates, rather than upfront discounts. Under this new arrangement, covered entities must purchase selected Medicare negotiation drugs at the wholesale acquisition cost (WAC) or negotiated prices, then seek a manufacturer refund for the difference to the 340B price. <Read More>
The 340B Debate Can’t Ignore Supply Chain Realities – September 23, 2026 - Healthcare distributors deliver roughly 15 million medicines and healthcare products every day to hospitals, physicians’ offices, pharmacies, and other providers across the country. While they play a critical role in keeping the healthcare supply chain moving, they are largely removed from the design and operation of the 340B Drug Pricing Program. As lawmakers debate changes to 340B, it is essential to recognize the distinct role distributors serve — and avoid policies that assign them responsibility for decisions they do not control. <Read More>
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data – September 18, 2026 - Johnson & Johnson now requires comprehensive pharmacy/medical claims elements to be submitted to its 340B ESP platform, with suspension of all 340B pricing within five business days after repeated noncompliance. Eli Lilly’s January 2026 policy expanded reporting to in-house dispensing and provider-administered drugs, enforcing 45–60 day deadlines and threatening termination, with suspensions already prompting litigation. <Read More>
Utilizing 340B Margin to Create a Patient Prescription Assistance Program – September 16, 2026 - Medicaid work/volunteer/school hour verification and 6-month renewals may drive coverage losses, disrupting continuity and access to specialty drugs among adults aged 19 to 64 years in expansion populations. Manufacturer restrictions on 340B pricing and claims-submission requirements add administrative burden and risk multimillion-dollar annual acquisition-cost increases for noncompliant safety-net health systems. Hospital-owned specialty pharmacies can fund PAPs with 340B savings to lower patient cost exposure, improve adherence, reduce abandonment, and mitigate reliance on external subsidies or foundations. <Read More>
Clinical Insights: October 1, 2026
New Drug/Vaccine Approval
Atebrioz™ (zilurgisertib) Tablets – New Drug Approval – September 25, 2026 – The U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (bone formation outside the skeleton) in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended starting dosage is 100 mg orally once daily with or without food. <Read More>
Onswik™ (insulin efsitora alfa-gobe) Injection - New Drug Approval – September 24, 2026 – Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin, indicated along with diet and exercise to control high blood sugar in adults with type 2 diabetes. Onswik™ is designed to deliver steady basal insulin levels over a full seven days. <Read More>
Lyrfigtu™ (lirafugratinib) Capsules – New Drug Approval – September 23, 2026 – The Food and Drug Administration approved lirafugratinib (Lyrfigtu™, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement. <Read More>
Fayuvi™ (rebisufligene etisparvovec-hopf) Suspension for Intravenous Infusion - formerly UX111 – New Drug Approval – September 17, 2026 – The U.S. Food and Drug Administration approved Fayuvi™ (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A., MPS IIIA is a rare inherited disease that progressively damages the brain and nervous system, causing children to lose cognitive, language and other developmental abilities over time. Until now, treatment was limited to managing symptoms; there was no FDA-approved therapy designed to change the underlying course of the disease. <Read More>
Bexlutry™ (lutetium Lu 177 dotatate) Injection – New Drug Approval – September 14, 2026 – Curium™ announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Bexlutry™ lutetium Lu 177 dotatate injection for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. <Read More>
Pixclara® (floretyrosine F 18) Injection – New Drug Approval – September 11, 2026 – Telix announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer). <Read More>
Isembyld™ (apitegromab-mstn) Injection – New Drug Approval – September 11, 2026 – Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, announced that the FDA has approved Isembyld™ (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. <Read More>
Etcamah™ (camizestrant) Tablets – New Drug Approval – September 4, 2026 – The Food and Drug Administration granted accelerated approval to camizestrant (Etcamah™, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test. <Read More>
Zanvastro™ (zilganersen) Injection – New Drug Approval – September 3, 2026 – The U.S. Food and Drug Administration has approved Zanvastro™ (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients. Zanvastro™ is the first FDA-approved treatment for Alexander disease and the first therapy to directly target the protein buildup that drives the disease. <Read More>
Omcazio™ (cabozantinib) Capsules – New Drug Approval – September 3, 2026 – Handa Pharmaceuticals, Inc. (“Handa” or the “Company”) (TSE:6620) announced that the U.S. Food and Drug Administration (“FDA”) has granted final approval to Omcazio™ (cabozantinib) capsules, the lauryl sulfate salt formulation of cabozantinib developed by the Company’s U.S. subsidiary, Handa Oncology, LLC. The action converts Handa’s prior tentative approval to final approval and authorizes Omcazio™ for commercialization in the United States. <Read More>
Mimrylo™ (rusfertide) Lyophilized Powder for Injection – New Drug Approval – August 28, 2026 – Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for Mimrylo™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. <Read More>
Bixlenvo™ (bictegravir and lenacapavir) Tablets – New Drug Approval – August 27, 2026 – Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo™ is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs. <Read More>
Lisraya™ (brepocitinib) Tablets – New Drug Approval – August 27, 2026 - The U.S. Food and Drug Administration has approved Lisraya™ (brepocitinib) tablets for the treatment of dermatomyositis in adults. For decades, dermatomyositis patients have had limited treatment options to manage their symptoms. The approval of Lisraya™ offers patients an important new alternative by providing an effective oral treatment option. <Read More>
Rasonque™ (daraxonrasib) Tablets – New Drug Approval – August 26, 2026 – The U.S. Food and Drug Administration approved Rasonque™ (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. <Read More>
New Label Expansions
Welireg® (belzutifan) Tablets – New Expanded Label – September 24, 2026 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced the U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of Welireg® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus Lenvima® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. <Read More>
Aqneursa® (levacetylleucine) Granules for Oral Suspension – New Expanded Label – September 18, 2026 – The U.S. Food and Drug Administration has approved Aqneursa® (levacetylleucine) for oral suspension to treat ataxia in adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg (about 33 pounds). Aqneursa® was previously approved in 2024 to treat the neurological manifestations of Niemann-Pick disease type C. This approval makes Aqneursa® the first treatment approved for ataxia in patients with ataxia-telangiectasia. <Read More>
Kerendia® (finerenone) Tablets – New Expanded Label – September 17, 2026 – Bayer announced that the U.S. Food and Drug Administration (FDA) approved Kerendia® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), following the agency’s Priority Review of the supplemental New Drug Application (sNDA). <Read More>
Ibtrozi® (taletrectinib) Capsules – New Expanded Label – September 16, 2026 – Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Ibtrozi® (taletrectinib), a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). <Read More>
Inluriyo® (imlunestrant) Tablets – New Expanded Label – September 16, 2026 – Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Inluriyo® (imlunestrant), an oral estrogen receptor (ER) antagonist, in combination with Verzenio® (abemaciclib), a CDK4/6 inhibitor, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated locally advanced or metastatic breast cancer (MBC), as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Joenja® (leniolisib) Tablets – New Expanded Label – September 11, 2026 – FDA has approved Joenja® (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children 4-11 years who weigh at least 27 kg. Joenja® was first approved in 2023 for the same indication in patients 12 years and older at a dose of 70 mg orally twice a day. Children 4-11 years take a weight-based dosage (40, 50, or 70 mg) orally twice a day, approximately 12 hours apart. <Read More>
Imdelltra® (tarlatamab-dlle) for Injection – New Expanded Label – September 11, 2026 – Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved an update to the Imdelltra® (tarlatamab-dlle) Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in an appropriate healthcare setting. This approval means that patients receiving Imdelltra® should now be monitored for 6 to 8 hours from the start of their first two infusions, compared with the previously recommended 22 to 24 hours. <Read More>
Ameluz® (aminolevulinic acid) Gel – New Expanded Label – September 9, 2026 – Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED® lamp series, for the treatment of superficial Basal Cell Carcinoma (sBCC) in adults. <Read More>
Hyrnuo® (sevabertinib) Tablets – New Expanded Label – September 9, 2026 – The Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo®, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. <Read More>
Stelara® (ustekinumab) Injection – New Expanded Label – August 28, 2026 – The U.S. Food and Drug Administration has approved Stelara® (ustekinumab) injection for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients aged 2 years old and older. On April 15, 2026, Stelara® was approved for the treatment of moderately to severely active Crohn’s disease (CD) in pediatric patients aged 2 years old and older. Stelara® is the first approved therapeutic monoclonal antibody that does not target human tumor necrosis factor alpha (TNFα) for the two main forms of pediatric inflammatory bowel disease. <Read More>
Besremi® (ropeginterferon alfa-2b-njft) Injection – New Expanded Label – August 28, 2026 – PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446) announced the U.S. Food and Drug Administration (FDA) has approved Besremi® (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), making it the first new FDA-approved treatment for ET in nearly three decades. Besremi® has been approved for adults with ET, regardless of their genotype or disease status, including newly diagnosed patients who are naive to cytoreductive therapy. <Read More>
Spikevax® (COVID-19 Vaccine, mRNA) Injection – New Expanded Label – August 27, 2026 – Moderna, Inc. (NASDAQ:MRNA) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19. <Read More>
Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted) Injectable Suspension – August 27, 2026 – Novavax, Inc.'s (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan. These approvals position Novavax to continue earning royalties on net sales in these markets this season. <Read More>
Comirnaty® (COVID-19 Vaccine, mRNA) Injection – New Expanded Label – August 27, 2026 – Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (Comirnaty® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. <Read More>
Mounjaro® (tirzepatide) Injection – New Expanded Label – August 27, 2026 – Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro® (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. <Read More>
Tevimbra® (tislelizumab-jsgr) Injection – New Expanded Label – August 25, 2026 – BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Tevimbra® (tislelizumab) in combination with Ziihera® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). <Read More>
New Drug Shortage
September 21, 2026
Arsenic Trioxide Injection (Discontinuation)
September 18, 2026
Rivaroxaban For Suspension (Discontinuation)
Rivastigmine Film, Extended Release (Discontinuation)
September 16, 2026
Melphalan Hydrochloride Injection (Discontinuation)
Mesalamine Capsule, Extended Release (Discontinuation)
September 11, 2026
Cisatracurium Besylate Injection (Discontinuation)
Micafungin Sodium Injection (Discontinuation)
September 10, 2026
Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution (Discontinuation)
Updated Drug Shortage
September 22, 2026
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Carboplatin Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Heparin Sodium Injection (Currently in Shortage)
Hydromorphone Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Lorazepam Injection (Currently in Shortage)
Midazolam Hydrochloride Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Sodium Bicarbonate Injection (Currently in Shortage)
September 21, 2026
Clindamycin Phosphate Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
September 18, 2026
Bumetanide Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Oral Solution (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lisdexamfetamine Dimesylate Capsule (Currently in Shortage)
Lisdexamfetamine Dimesylate Tablet, Chewable (Currently in Shortage)
Methotrexate Sodium Injection (Currently in Shortage)
Methylphenidate Hydrochloride Tablet, Extended Release (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Promethazine Hydrochloride Injection (Currently in Shortage)
Technetium TC-99M Pyrophosphate Kit Injection (Currently in Shortage)
September 17, 2026
Carboplatin Injection (Currently in Shortage)
Clindamycin Phosphate Injection (Currently in Shortage)
Dextrose Monohydrate 10% Injection (Currently in Shortage)
Dextrose Monohydrate 5% Injection (Currently in Shortage)
Dextrose Monohydrate 70% Injection (Currently in Shortage)
Ifosfamide Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
September 16, 2026
Desmopressin Acetate Spray (Currently in Shortage)
Lisdexamfetamine Dimesylate Capsule (Currently in Shortage)
Streptozocin Powder, For Solution (Currently in Shortage)
New Drug Recall and Safety Alerts
Par Health Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection – September 18, 2026 - Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose or stopper material. <Read More>
Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP – September 17, 2026 - Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% Sodium Chloride Injection, USP, 100mL single pack to the user level due to a potential mix-up. The affected lot of 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23 Lot 1042188) may potentially contain the overwrap with labeling indicating it to be 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23) but the actual product within the overwrap may be Potassium Chloride Inj. 10 mEq, (NDC 0990-7074-26) Lot 1035181. <Read More>
B. Braun Medical Inc. Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container – September 3, 2026 - B. Braun Medical Inc (B. Braun) is voluntarily recalling three (3) lots of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container, to the hospital/healthcare facility/user level due to presence of particulate matter identified as iron oxide, inorganic, cellulose or polystyrene particulate matter. <Read More>
Baxter Issues Voluntary Nationwide Recall for Two Lots of 0.9% Sodium Chloride Injection – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling two lots of 0.9% Sodium Chloride Injection due to the potential presence of particulate matter identified as fiberglass in the solution. <Read More>
Baxter Issues Voluntary Nationwide Recall for One Lot of Anticoagulant Sodium Citrate Solution – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of Anticoagulant Sodium Citrate Solution due to the potential presence of particulate matter identified as fiberglass in the solution. <Read More>
Baxter Issues Voluntary Nationwide Recall for One Lot of 70% Dextrose Injection – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of 70% Dextrose Injection due to the potential presence of particulate matter identified as stainless steel particles in the solution. <Read More>
New Generic/Biosimilar Approval and Launch
Bravnetsa™ (lutetium Lu 177 dotatate) Injection – New Lutathera® Biosimilar Approval – September 21, 2026 – Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Bravnetsa™ (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to Lutathera® (lutetium Lu 177 dotatate). <Read More>
Clinical and Pharmacy News
Navigating GLP-1 Switches: A Guide for Primary Care – September 29, 2026 - As GLP-1 receptor agonists and dual incretin agents become more common in treating obesity and type 2 diabetes, primary care providers are handling more medication switches. The reason may be insurance coverage, ongoing gastrointestinal side effects, inadequate response, or the need for better blood sugar control or weight support. Whatever the driver, switching is not simply trading one prescription for another. It requires planning around half-lives, dose history, side effects, and the risk for blood sugar swings. <Read More>
Insurance Coverage Lags as Cancer Science, Treatment Move Forward – September 24, 2026 - Eighteen months after his initial diagnosis, chemotherapy hadn’t slowed 21-year-old Mason Henderson’s rare brain tumor, which had spread to his spinal fluid. So, he left his home in southeastern Texas to spend three weeks in a clinical trial in New York City. But that failed, too, leaving a murky path for Henderson, whose cancer was so rare the World Health Organization had only given it a name in 2021. So early this year, Henderson’s doctors, evaluating his tumor’s deep genetic language, turned to a drug made by Merck and AstraZeneca called Lynparza®. <Read More>
Cholesterol Control Gets Personalized—How New Guidelines Tailor Treatment to Your Unique Risk Profile – September 24, 2026 – As a cardiologist with expertise in sports and exercise science, I routinely care for patients who want to make healthy lifestyle choices to control their cholesterol levels, reduce their risk of cardiovascular disease and improve their overall health. In March 2026, the American Heart Association and the American College of Cardiology issued new guidelines on how to treat dyslipidemia. The guidelines, last updated in 2018, incorporate findings from several new studies on how to more effectively treat—and prevent—the condition. The new guidelines can help doctors personalize treatment to reduce each patient's risk of developing cardiovascular disease. <Read More>
VA/DoD Release Updated Tobacco Cessation Clinical Practice Guidelines – September 22, 2026 - The US Department of Veterans Affairs (VA) and Department of Defense (DoD) have released an updated clinical practice guideline recommending varenicline or combination nicotine replacement therapy as the preferred treatments for tobacco cessation, according to a synopsis published in Annals of Internal Medicine. The updated guidance addresses nicotine and tobacco use among service members and veterans, noting that use leads to adverse physical and mental health effects, and reduces military force readiness. For respiratory therapists and allied healthcare professionals treating patients with chronic lung conditions and nicotine dependence, the document outlines practical strategies to improve long-term abstinence rates. <Read More>
Generic Drug Costs Burdening Patients as Much as Brand Name Options – September 18, 2026 - Aggregate OOP burden for generics exceeds brands due to utilization intensity, especially among Medicare beneficiaries with higher generic fill counts and near-parity annual OOP spending versus brands. Cost-related nonadherence remains substantial, with reported treatment abandonment and dose modification, positioning community pharmacists as key actors in mitigating downstream acute-care utilization. <Read More>
Specialty Pharmacy Leaders to Convene for NASP inSPire2026 – September 18, 2026 - As specialty pharmacy addresses the rising cost and complexity of cell and gene therapies, this year's newly rebranded inSPire2026 meeting will bring pharmacists, nurses, and industry leaders together to chart how those breakthroughs actually reach patients. From September 22 to 25, 2026, specialty pharmacy professionals gathered for inSPire2026, the newly rebranded successor to the National Association of Specialty Pharmacy's (NASP) Annual Meeting & Expo. <Read More>
340B in the News
340B Hospitals Lag Behind Peers in Charity Care Spending: Report – September 25, 2026 - A new report from a conservative think tank is accusing 340B hospitals of providing less charity care than other nonprofit hospitals, despite receiving discounted drugs. Hospitals participating in the 340B drug discount program spent 2.16% of their operating expenses on free or discounted care for low-income patients, called charity care, compared with 2.82% at non-340B hospitals, according to a Thursday analysis from the Pioneer Institute and CancerCare. <Read More>
What the Revised 340B Rebate Pilot Programme Means for Pharma Revenue Operations – September 24, 2026 - The US government's revised 340B rebate pilot programme signals that pharmaceutical manufacturers need to prepare their operations for the next phase of drug discount management. The pilot shifts how pharmaceutical manufacturers provide 340B discounts to eligible hospitals and healthcare providers. The savings for certain medications will now come in the form of rebates, rather than upfront discounts. Under this new arrangement, covered entities must purchase selected Medicare negotiation drugs at the wholesale acquisition cost (WAC) or negotiated prices, then seek a manufacturer refund for the difference to the 340B price. <Read More>
The 340B Debate Can’t Ignore Supply Chain Realities – September 23, 2026 - Healthcare distributors deliver roughly 15 million medicines and healthcare products every day to hospitals, physicians’ offices, pharmacies, and other providers across the country. While they play a critical role in keeping the healthcare supply chain moving, they are largely removed from the design and operation of the 340B Drug Pricing Program. As lawmakers debate changes to 340B, it is essential to recognize the distinct role distributors serve — and avoid policies that assign them responsibility for decisions they do not control. <Read More>
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data – September 18, 2026 - Johnson & Johnson now requires comprehensive pharmacy/medical claims elements to be submitted to its 340B ESP platform, with suspension of all 340B pricing within five business days after repeated noncompliance. Eli Lilly’s January 2026 policy expanded reporting to in-house dispensing and provider-administered drugs, enforcing 45–60 day deadlines and threatening termination, with suspensions already prompting litigation. <Read More>
Utilizing 340B Margin to Create a Patient Prescription Assistance Program – September 16, 2026 - Medicaid work/volunteer/school hour verification and 6-month renewals may drive coverage losses, disrupting continuity and access to specialty drugs among adults aged 19 to 64 years in expansion populations. Manufacturer restrictions on 340B pricing and claims-submission requirements add administrative burden and risk multimillion-dollar annual acquisition-cost increases for noncompliant safety-net health systems. Hospital-owned specialty pharmacies can fund PAPs with 340B savings to lower patient cost exposure, improve adherence, reduce abandonment, and mitigate reliance on external subsidies or foundations. <Read More>
Clinical Insights: August 27, 2026
New Drug/Vaccine Approval
Pasatru™ (garetosmab-grts) Injection – New Drug Approval – August 19, 2026 - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Recognizing the significant mobility challenges faced by many people with FOP, Pasatru can be administered across a range of care settings, including home infusion where appropriate. <Read More>
Genglycos™ (pariglasgene brecaparvovec-opnr) Suspension for Intravenous Infusion - formerly DTX401 – New Drug Approval – August 19, 2026 - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Genglycos™ (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). <Read More>
Zenbexus™ (iberdomide) Capsules – New Drug Approval – August 13, 2026 - The Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus™, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. <Read More>
Tauklarify™ (florquinitau F 18) Injection - formerly MK-6240 – New Drug Approval – August 13, 2026 - Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced U.S. Food and Drug Administration (FDA) approval of Tauklarify™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease to identify patients with tau neurofibrillary tangle (NFT) pathology. <Read More>
Tudriqev™ (vusolimogene oderparepvec-wtpg) Suspension for Intratumor Injection – New Drug Approval – August 6, 2026 - The Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev™, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. <Read More>
Orzeyful™ (oveporexton) Tablets – New Drug Approval – August 5, 2026 - Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved Orzeyful™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people's lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. <Read More>
mFLUSIVA® (influenza vaccine, mRNA) Injection - formerly mRNA-1010 – New Drug Approval – August 5, 2026 - Moderna, Inc. (NASDAQ:MRNA) announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) supporting mFLUSIVA® – for adults 50 years of age and older. <Read More>
Gwyn Lo™ (ethinyl estradiol and norelgestromin) Transdermal System – New Drug Approval – July 28, 2026 - Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system). Gwyn Lo™ is a new combined hormonal contraceptive (CHC) patch with low-dose estrogen. The patch has demonstrated contraceptive efficacy for women of childbearing potential with a body mass index (BMI) below 30 kg/m® who are appropriate candidates for CHC. The Gwyn Lo™ dosage is norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day. <Read More>
New Label Expansions
Imaavy® (nipocalimab-aahu) Injection – New Expanded Label – August 24, 2026 – Johnson & Johnson (NYSE: JNJ) announced the U.S. Food and Drug Administration (FDA) approval of Imaavy® (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) – a rare, life-threatening autoantibody disease – in adults and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. <Read More>
Lerochol® (lerodalcibep-liga) Injection - New Expanded Label – August 13, 2026 – LIB Therapeutics, Inc. (LIB)… announced the U.S. Food and Drug Administration (FDA) has approved an autoinjector for Lerochol® (lerodalcibep-liga) Injection 300 mg/1.2 mL, a third-generation Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor that combines robust and sustained efficacy with once-monthly, single injection self-administration to support long-term adherence. <Read More>
Pluvicto® (lutetium lu 177 vipivotide tetraxetan) Injection - New Expanded Label – July 31, 2026 - Novartis announced the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive (mAPMN/S) prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer (mHSPC). <Read More>
New Drug Shortage
August 25, 2026
Liraglutide Injection (Discontinuation)
Mesalamine Capsule, Extended Release (Discontinuation)
August 24, 2026
Disopyramide Phosphate Capsule, Extended Release (Discontinuation)
August 14, 2026
Fulvestrant Injection (Discontinuation)
August 13, 2026
Diclofenac Sodium Tablet, Delayed Release (Discontinuation)
Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution (Discontinuation)
August 10, 2026
Glyburide Tablet (Discontinuation)
Updated Drug Shortage
August 25, 2026
Dexamethasone Sodium Phosphate Injection (Currently in Shortage)
Liraglutide Injection (Currently in Shortage)
Rifampin Injection (Currently in Shortage)
August 24, 2026
Atropine Sulfate Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Desmopressin Acetate Spray (Currently in Shortage)
Dextrose Monohydrate 50% Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
August 21, 2026
Bumetanide Injection (Currently in Shortage)
August 20, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
August 18, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
Clindamycin Phosphate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Metronidazole Injection (Currently in Shortage)
Rifampin Capsule (Currently in Shortage)
New Drug Recall and Safety Alerts
Thyroid Tablets, USP 30 mg by Vitruvias Therapeutics, Inc – New Voluntary Recall – August 21, 2026 - Vitruvias Therapeutics Inc. is voluntarily recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg to the consumer level. The product is being recalled because testing confirmed the potential for the product to be superpotent. <Read More>
Glutathione 200 mg/mL Multi-Dose Vials by Optimal Balance Pharmacy – New Voluntary Recall – August 19, 2026 - Optimal Balance Pharmacy is voluntarily recalling one lot of Compounded Glutathione 200 MG/ML 30 ML Multi-Dose Vials to the patient level. The product is being recalled because pharmacy testing identified elevated bacterial endotoxin levels. <Read More>
Excel® Lactated Ringers Injection, 1000mL by B. Braun Medical Inc. – New Voluntary Recall – August 19, 2026 - B. Braun Medical Inc (B. Braun), is voluntarily recalling one lot of Excel® Lactated Ringers Injection, 1000mL to the hospital/healthcare facility level, due to the presence of particulate matter in solution identified primarily as cellulose cotton fibers, with individual particles also identified as cellulose wood fiber and polystyrene. <Read More>
Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials by Fresenius Kabi – New Voluntary Recall – August 10, 2026 - Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. <Read More>
Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe by Fresenius Kabi – New Voluntary Recall – August 4, 2026 - Fresenius Kabi, an operating company of the Fresenius Group, is voluntarily recalling one lot of Morphine Sulfate Injection USP, Simplist® – 2 mg/1 mL due to a label mix-up. The MicroVault labeled as morphine 2 mg/1 mL, may contain a Prefilled Syringe of Dilaudid® – 0.5 mg/0.5 mL. This recall is being conducted to the user level. <Read More>
Optiray® Imaging Bulk Package - 350, 500mL, Vial by Liebel-Flarsheim Company, LLC – New Voluntary Recall – July 31, 2026 - Liebel-Flarsheim Company, LLC, is recalling one lot of Optiray® Imaging Bulk Package (IBP) 350, 500mL in vial, (Ioversol Injection 74% 350 mg iodine/ml) for intra-arterial or intra-venous use to the user level (hospitals, imaging centers, healthcare facilities and clinics, and other potential users of the product) due to the presence of particulate matter comprising polyethylene and other plastic materials, stainless steel and glass. <Read More>
New Generic/Biosimilar Approval and Launch
No new update
Clinical and Pharmacy News
Hidden Single-Source Risk Behind Generic Drug Supply – August 24, 2026 - Healthcare procurement teams have spent years building redundancy into pharmaceutical purchasing. A critical generic may have multiple approved manufacturers, multiple distributors and several products available for substitution, and on paper that looks diversified. Upstream, it can be something very different, and the deeper problem is that the usual numbers can still understate just how concentrated that dependency really is. <Read More>
Fewer Employers are Covering GLP-1 Drugs for Weight Loss. Should They? – August 24, 2026 - Two recent news items reveal countervailing trends in employer health insurance coverage for GLP-1 drugs, the highly effective and highly expensive medications for treating diabetes and obesity. The insurer Cigna reported a pullback in coverage of GLP-1 drugs for weight loss. Six percent of large employers dropped coverage in 2026, according to Bloomberg. Meanwhile, Bank of America is doubling down. It's continuing to cover GLP-1s for weight loss (in addition to covering them to treat diabetes), while also providing healthcare and lifestyle coaching for those on the drugs – at a cost of $250 million a year. That now represents 13% of the company's total healthcare spending. <Read More>
REMS Removed: Why CAR-T's Expansion into Community Oncology Could Benefit the Big Three Wholesalers – August 18, 2026 – The FDA's removal of CAR-T REMS requirements eliminates one obstacle to expanding treatment beyond traditional academic medical centers. That change could disproportionately benefit the Big Three wholesalers, which have spent billions building positions in community oncology while simultaneously investing in cell-and-gene-therapy distribution and support infrastructure. <Read More>
Panel Offers First Guidelines for Using E-Cigarettes to Help Smokers Quit – August 18, 2026 - A panel of experts has issued the first clinical guidelines for using e-cigarettes to help adults quit smoking. E-cigarettes should be offered alongside other smoking cessation strategies like nicotine replacement therapies or medications like varenicline and bupropion, a panel from the Society for Research on Nicotine and Tobacco said. Its recommendations were published recently in the Journal of the American Medical Association. <Read More>
States Should Not Wait Until 2028 to Open PBMs' Books – August 18, 2026 - Prescription drug prices do not become opaque by accident. They become opaque because the middlemen who manage drug benefits are allowed to hide many of their revenue streams from the employers, insurers, pharmacies, and patients who ultimately pay the bill. Congress has already recognized the problem. Federal pharmacy benefit manager (PBM) reporting requirements are scheduled to reshape what PBMs must disclose, but many of the most important provisions will not take effect until 2028. That delay creates a basic question for state lawmakers: why wait? <Read More>
Clinical Guidance: Malaria Diagnosis and Treatment in the U.S. – August 17, 2026 - Approximately 2,000 cases of malaria are reported annually in the United States, primarily among travelers. Malaria can be a severe, potentially fatal disease. Urgent diagnosis followed by immediate treatment is critical. Healthcare providers in the United States can use this guidance to ensure appropriate diagnosis and treatment of malaria. As of August 2026, guidance extends artemether-lumefantrine duration to 5 days (10 doses) for Plasmodium falciparum malaria, both for the treatment of uncomplicated infections and following IV artesunate for severe infections. <Read More>
Employers Tighten Benefits Cost Oversight as Medical and Pharmacy Pressures Mount – August 17, 2026 - More than a third of employers reported health plan premium increases of 10% or more at their latest renewal, and pharmacy and voluntary benefits are facing similar scrutiny, according to Gallagher. Medical cost pressure is intensifying even as employers make changes to health care plans intended to control it, according to Gallagher's U.S. Benefits Strategy & Benchmarking Survey. <Read More>
Major PBMs to Boost Prescription Drug Price Transparency Through TrumpRx – August 13, 2026 - A group of nine pharmacy benefit managers (PBMs) announced Thursday that they will work with an industry group to boost the transparency of prescription drug pricing through the TrumpRx platform. Fox Business exclusively learned that the Pharmaceutical Care Management Association (PCMA) and nine PBMs reached an agreement to showcase the cash price of prescriptions from TrumpRx within their benefit tools. The agreement aims to give patients better visibility into the cost of the medication and how they might save money on it. <Read More>
Employer Survey Signals Coming Shakeup in PBM Market Dynamics – August 13, 2026 – Employers are increasingly shifting business away from the big three pharmacy benefit managers of Express Scripts Inc., CVS Caremark and UnitedHealth Group's OptumRx, according to a survey released Wednesday. The three companies – which manage prescription drugs for health plans – are believed to control 80% of the market, and have garnered blowback from Congress and state regulators over opaque pricing practices and pressure on local pharmacies. <Read More>
From Blame to Data: How Medication Error Reporting Systems Drive Patient Safety – August 12, 2026 - A single medication error can have devastating consequences for patients, pharmacists, and institutions. Globally, medication-related errors are responsible for approximately 5% to 41% of all hospital admissions and 22% of readmissions. The annual costs associated with medication errors globally are approximately $42 billion. Error reporting and analysis can only decrease error rates if health care shifts its culture from one of punitive blame to one that treats errors as systemic data points for identification and correction. This requires a robust, nonpunitive reporting system coupled with systematic analysis to prevent future harm. <Read More>
The New Era of Pharma Distribution: Balancing Precision and Scale – July 14, 2026 - Specialty medicines comprise ~75% of ~7,000 pipeline assets, with nearly 180 advanced therapies expected by 2030, accelerating demand for scalable, operationally sustainable distribution models. Cold-chain exposure is rising, with ~50% of launches through 2027 requiring temperature control; 3PLs are expanding ambient-to-cryogenic capacity, including ultra-low and liquid-nitrogen storage. <Read More>
340B in the News
HRSA Revives the 340B Rebate Pilot: Covered Entities Should Prepare Now for 2027 – August 18, 2026 - HRSA is again moving toward a 340B rebate model, and covered entities should begin preparing for the possibility that the way they purchase certain 340B drugs will change on January 1, 2027. On July 31, 2026, the Health Resources and Services Administration (HRSA) announced a revised 340B Rebate Model Pilot Program. The proposal would allow qualifying manufacturers to provide the 340B ceiling price for certain drugs through a post-purchase rebate rather than the upfront discount that has long been the norm in the 340B Program. <Read More>
340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs – July 7, 2026 – CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes $1.15 billion lower Original Medicare beneficiary drug costs and $4.55 billion reduced taxpayer spending, with OPPS budget neutrality offsetting via increased non-drug payments. <Read More>
Clinical Insights: August 27, 2026
New Drug/Vaccine Approval
Pasatru™ (garetosmab-grts) Injection – New Drug Approval – August 19, 2026 - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Recognizing the significant mobility challenges faced by many people with FOP, Pasatru can be administered across a range of care settings, including home infusion where appropriate. <Read More>
Genglycos™ (pariglasgene brecaparvovec-opnr) Suspension for Intravenous Infusion - formerly DTX401 – New Drug Approval – August 19, 2026 - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Genglycos™ (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). <Read More>
Zenbexus™ (iberdomide) Capsules – New Drug Approval – August 13, 2026 - The Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus™, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. <Read More>
Tauklarify™ (florquinitau F 18) Injection - formerly MK-6240 – New Drug Approval – August 13, 2026 - Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced U.S. Food and Drug Administration (FDA) approval of Tauklarify™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease to identify patients with tau neurofibrillary tangle (NFT) pathology. <Read More>
Tudriqev™ (vusolimogene oderparepvec-wtpg) Suspension for Intratumor Injection – New Drug Approval – August 6, 2026 - The Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev™, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. <Read More>
Orzeyful™ (oveporexton) Tablets – New Drug Approval – August 5, 2026 - Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved Orzeyful™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people's lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. <Read More>
mFLUSIVA® (influenza vaccine, mRNA) Injection - formerly mRNA-1010 – New Drug Approval – August 5, 2026 - Moderna, Inc. (NASDAQ:MRNA) announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) supporting mFLUSIVA® – for adults 50 years of age and older. <Read More>
Gwyn Lo™ (ethinyl estradiol and norelgestromin) Transdermal System – New Drug Approval – July 28, 2026 - Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system). Gwyn Lo™ is a new combined hormonal contraceptive (CHC) patch with low-dose estrogen. The patch has demonstrated contraceptive efficacy for women of childbearing potential with a body mass index (BMI) below 30 kg/m® who are appropriate candidates for CHC. The Gwyn Lo™ dosage is norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day. <Read More>
New Label Expansions
Imaavy® (nipocalimab-aahu) Injection – New Expanded Label – August 24, 2026 – Johnson & Johnson (NYSE: JNJ) announced the U.S. Food and Drug Administration (FDA) approval of Imaavy® (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) – a rare, life-threatening autoantibody disease – in adults and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. <Read More>
Lerochol® (lerodalcibep-liga) Injection - New Expanded Label – August 13, 2026 – LIB Therapeutics, Inc. (LIB)… announced the U.S. Food and Drug Administration (FDA) has approved an autoinjector for Lerochol® (lerodalcibep-liga) Injection 300 mg/1.2 mL, a third-generation Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor that combines robust and sustained efficacy with once-monthly, single injection self-administration to support long-term adherence. <Read More>
Pluvicto® (lutetium lu 177 vipivotide tetraxetan) Injection - New Expanded Label – July 31, 2026 - Novartis announced the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive (mAPMN/S) prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer (mHSPC). <Read More>
New Drug Shortage
August 25, 2026
Liraglutide Injection (Discontinuation)
Mesalamine Capsule, Extended Release (Discontinuation)
August 24, 2026
Disopyramide Phosphate Capsule, Extended Release (Discontinuation)
August 14, 2026
Fulvestrant Injection (Discontinuation)
August 13, 2026
Diclofenac Sodium Tablet, Delayed Release (Discontinuation)
Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution (Discontinuation)
August 10, 2026
Glyburide Tablet (Discontinuation)
Updated Drug Shortage
August 25, 2026
Dexamethasone Sodium Phosphate Injection (Currently in Shortage)
Liraglutide Injection (Currently in Shortage)
Rifampin Injection (Currently in Shortage)
August 24, 2026
Atropine Sulfate Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Desmopressin Acetate Spray (Currently in Shortage)
Dextrose Monohydrate 50% Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
August 21, 2026
Bumetanide Injection (Currently in Shortage)
August 20, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
August 18, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
Clindamycin Phosphate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Metronidazole Injection (Currently in Shortage)
Rifampin Capsule (Currently in Shortage)
New Drug Recall and Safety Alerts
Thyroid Tablets, USP 30 mg by Vitruvias Therapeutics, Inc – New Voluntary Recall – August 21, 2026 - Vitruvias Therapeutics Inc. is voluntarily recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg to the consumer level. The product is being recalled because testing confirmed the potential for the product to be superpotent. <Read More>
Glutathione 200 mg/mL Multi-Dose Vials by Optimal Balance Pharmacy – New Voluntary Recall – August 19, 2026 - Optimal Balance Pharmacy is voluntarily recalling one lot of Compounded Glutathione 200 MG/ML 30 ML Multi-Dose Vials to the patient level. The product is being recalled because pharmacy testing identified elevated bacterial endotoxin levels. <Read More>
Excel® Lactated Ringers Injection, 1000mL by B. Braun Medical Inc. – New Voluntary Recall – August 19, 2026 - B. Braun Medical Inc (B. Braun), is voluntarily recalling one lot of Excel® Lactated Ringers Injection, 1000mL to the hospital/healthcare facility level, due to the presence of particulate matter in solution identified primarily as cellulose cotton fibers, with individual particles also identified as cellulose wood fiber and polystyrene. <Read More>
Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials by Fresenius Kabi – New Voluntary Recall – August 10, 2026 - Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. <Read More>
Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe by Fresenius Kabi – New Voluntary Recall – August 4, 2026 - Fresenius Kabi, an operating company of the Fresenius Group, is voluntarily recalling one lot of Morphine Sulfate Injection USP, Simplist® – 2 mg/1 mL due to a label mix-up. The MicroVault labeled as morphine 2 mg/1 mL, may contain a Prefilled Syringe of Dilaudid® – 0.5 mg/0.5 mL. This recall is being conducted to the user level. <Read More>
Optiray® Imaging Bulk Package - 350, 500mL, Vial by Liebel-Flarsheim Company, LLC – New Voluntary Recall – July 31, 2026 - Liebel-Flarsheim Company, LLC, is recalling one lot of Optiray® Imaging Bulk Package (IBP) 350, 500mL in vial, (Ioversol Injection 74% 350 mg iodine/ml) for intra-arterial or intra-venous use to the user level (hospitals, imaging centers, healthcare facilities and clinics, and other potential users of the product) due to the presence of particulate matter comprising polyethylene and other plastic materials, stainless steel and glass. <Read More>
New Generic/Biosimilar Approval and Launch
No new update
Clinical and Pharmacy News
Hidden Single-Source Risk Behind Generic Drug Supply – August 24, 2026 - Healthcare procurement teams have spent years building redundancy into pharmaceutical purchasing. A critical generic may have multiple approved manufacturers, multiple distributors and several products available for substitution, and on paper that looks diversified. Upstream, it can be something very different, and the deeper problem is that the usual numbers can still understate just how concentrated that dependency really is. <Read More>
Fewer Employers are Covering GLP-1 Drugs for Weight Loss. Should They? – August 24, 2026 - Two recent news items reveal countervailing trends in employer health insurance coverage for GLP-1 drugs, the highly effective and highly expensive medications for treating diabetes and obesity. The insurer Cigna reported a pullback in coverage of GLP-1 drugs for weight loss. Six percent of large employers dropped coverage in 2026, according to Bloomberg. Meanwhile, Bank of America is doubling down. It's continuing to cover GLP-1s for weight loss (in addition to covering them to treat diabetes), while also providing healthcare and lifestyle coaching for those on the drugs – at a cost of $250 million a year. That now represents 13% of the company's total healthcare spending. <Read More>
REMS Removed: Why CAR-T's Expansion into Community Oncology Could Benefit the Big Three Wholesalers – August 18, 2026 – The FDA's removal of CAR-T REMS requirements eliminates one obstacle to expanding treatment beyond traditional academic medical centers. That change could disproportionately benefit the Big Three wholesalers, which have spent billions building positions in community oncology while simultaneously investing in cell-and-gene-therapy distribution and support infrastructure. <Read More>
Panel Offers First Guidelines for Using E-Cigarettes to Help Smokers Quit – August 18, 2026 - A panel of experts has issued the first clinical guidelines for using e-cigarettes to help adults quit smoking. E-cigarettes should be offered alongside other smoking cessation strategies like nicotine replacement therapies or medications like varenicline and bupropion, a panel from the Society for Research on Nicotine and Tobacco said. Its recommendations were published recently in the Journal of the American Medical Association. <Read More>
States Should Not Wait Until 2028 to Open PBMs' Books – August 18, 2026 - Prescription drug prices do not become opaque by accident. They become opaque because the middlemen who manage drug benefits are allowed to hide many of their revenue streams from the employers, insurers, pharmacies, and patients who ultimately pay the bill. Congress has already recognized the problem. Federal pharmacy benefit manager (PBM) reporting requirements are scheduled to reshape what PBMs must disclose, but many of the most important provisions will not take effect until 2028. That delay creates a basic question for state lawmakers: why wait? <Read More>
Clinical Guidance: Malaria Diagnosis and Treatment in the U.S. – August 17, 2026 - Approximately 2,000 cases of malaria are reported annually in the United States, primarily among travelers. Malaria can be a severe, potentially fatal disease. Urgent diagnosis followed by immediate treatment is critical. Healthcare providers in the United States can use this guidance to ensure appropriate diagnosis and treatment of malaria. As of August 2026, guidance extends artemether-lumefantrine duration to 5 days (10 doses) for Plasmodium falciparum malaria, both for the treatment of uncomplicated infections and following IV artesunate for severe infections. <Read More>
Employers Tighten Benefits Cost Oversight as Medical and Pharmacy Pressures Mount – August 17, 2026 - More than a third of employers reported health plan premium increases of 10% or more at their latest renewal, and pharmacy and voluntary benefits are facing similar scrutiny, according to Gallagher. Medical cost pressure is intensifying even as employers make changes to health care plans intended to control it, according to Gallagher's U.S. Benefits Strategy & Benchmarking Survey. <Read More>
Major PBMs to Boost Prescription Drug Price Transparency Through TrumpRx – August 13, 2026 - A group of nine pharmacy benefit managers (PBMs) announced Thursday that they will work with an industry group to boost the transparency of prescription drug pricing through the TrumpRx platform. Fox Business exclusively learned that the Pharmaceutical Care Management Association (PCMA) and nine PBMs reached an agreement to showcase the cash price of prescriptions from TrumpRx within their benefit tools. The agreement aims to give patients better visibility into the cost of the medication and how they might save money on it. <Read More>
Employer Survey Signals Coming Shakeup in PBM Market Dynamics – August 13, 2026 – Employers are increasingly shifting business away from the big three pharmacy benefit managers of Express Scripts Inc., CVS Caremark and UnitedHealth Group's OptumRx, according to a survey released Wednesday. The three companies – which manage prescription drugs for health plans – are believed to control 80% of the market, and have garnered blowback from Congress and state regulators over opaque pricing practices and pressure on local pharmacies. <Read More>
From Blame to Data: How Medication Error Reporting Systems Drive Patient Safety – August 12, 2026 - A single medication error can have devastating consequences for patients, pharmacists, and institutions. Globally, medication-related errors are responsible for approximately 5% to 41% of all hospital admissions and 22% of readmissions. The annual costs associated with medication errors globally are approximately $42 billion. Error reporting and analysis can only decrease error rates if health care shifts its culture from one of punitive blame to one that treats errors as systemic data points for identification and correction. This requires a robust, nonpunitive reporting system coupled with systematic analysis to prevent future harm. <Read More>
The New Era of Pharma Distribution: Balancing Precision and Scale – July 14, 2026 - Specialty medicines comprise ~75% of ~7,000 pipeline assets, with nearly 180 advanced therapies expected by 2030, accelerating demand for scalable, operationally sustainable distribution models. Cold-chain exposure is rising, with ~50% of launches through 2027 requiring temperature control; 3PLs are expanding ambient-to-cryogenic capacity, including ultra-low and liquid-nitrogen storage. <Read More>
340B in the News
HRSA Revives the 340B Rebate Pilot: Covered Entities Should Prepare Now for 2027 – August 18, 2026 - HRSA is again moving toward a 340B rebate model, and covered entities should begin preparing for the possibility that the way they purchase certain 340B drugs will change on January 1, 2027. On July 31, 2026, the Health Resources and Services Administration (HRSA) announced a revised 340B Rebate Model Pilot Program. The proposal would allow qualifying manufacturers to provide the 340B ceiling price for certain drugs through a post-purchase rebate rather than the upfront discount that has long been the norm in the 340B Program. <Read More>
340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs – July 7, 2026 – CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes $1.15 billion lower Original Medicare beneficiary drug costs and $4.55 billion reduced taxpayer spending, with OPPS budget neutrality offsetting via increased non-drug payments. <Read More>
Ready to get started?
The Pillr Health team is here to empower your 340B program, and beyond. Reach out at the link below.
Ready to get started?
The Pillr Health team is here to empower your 340B program, and beyond. Reach out at the link below.
